CINXE.COM

<!DOCTYPE html> <html lang="en"> <head id="Head1"><meta name="viewport" content="width=device-width, initial-scale=1.0" /><meta http-equiv="X-UA-Compatible" content="IE=edge" /><title> Pre-Conference Programs - Nov. 6-7 - SITC 2024 </title><meta name='audience' content='ALL' /><meta name='rating' content='General' /><meta name='distribution' content='Global, Worldwide' /><meta name='copyright' content='Higher Logic, LLC' /><meta name='content-language' content='EN' /><meta name='referrer' content='strict-origin-when-cross-origin' /><meta name="apple-itunes-app" content="app-id=1555408470, app-argument=http://www.sitcancer.org/2024/schedule/sitc24-preconference"><link rel='SHORTCUT ICON' href='//higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC24_Favicon.png' type='image/png' /><link href='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/Font-Awesome/6.4.2-pro/css/all.min.css' type='text/css' rel='stylesheet' /><link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/themes/prism.min.css" integrity="sha512-tN7Ec6zAFaVSG3TpNAKtk4DOHNpSwKHxxrsiw4GHKESGPs5njn/0sMCUMl2svV4wo4BK/rCP7juYz+zx+l6oeQ==" crossorigin="anonymous" referrerpolicy="no-referrer" /><link href='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/bootstrap/3.4.1/css/bootstrap.min.css' rel='stylesheet' /><link type='text/css' rel='stylesheet' href='https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/Bundles/Desktop_bundle.min.d7804150d2a3d23b0f7bd53234959d21d94a14f1.hash.css'/><link href='https://ajax.googleapis.com/ajax/libs/jqueryui/1.10.1/themes/base/jquery-ui.css' type='text/css' rel='stylesheet' /><link href='https://d132x6oi8ychic.cloudfront.net/higherlogic/microsite/generatecss/2b495af7-ef43-40d3-8f8d-d42fc2073d1a/c4603878-5e01-4a39-8159-01899f20c254/638681333986830000/34' type='text/css' rel='stylesheet' /><link type='text/css' rel='stylesheet' href='https://cdn.jsdelivr.net/npm/instantsearch.css@8.0.0/themes/satellite-min.css' /><link type='text/css' rel='stylesheet' href='https://maxcdn.bootstrapcdn.com/font-awesome/4.5.0/css/font-awesome.min.css' /><link type='text/css' rel='stylesheet' href='https://fonts.googleapis.com/css?family=Dosis:500,700' /><link type='text/css' rel='stylesheet' href='https://fonts.googleapis.com/css?family=Open+Sans:400,700' /><link type='text/css' rel='stylesheet' href='https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick.css' /><link type='text/css' rel='stylesheet' href='https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick-theme.css' /><link type='text/css' rel='stylesheet' href='https://use.typekit.net/cqp4ikw.css' /><link type='text/css' rel='stylesheet' href='https://use.typekit.net/zyl7cfs.css' /><script type='text/javascript' src='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/JavaScript/promise-fetch-polyfill.js'></script><script type='text/javascript' src='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/JavaScript/systemjs/3.1.6/system.min.js'></script><script type='systemjs-importmap' src='/HigherLogic/JavaScript/importmapping-cdn.json?638682702504999917'></script><script type='text/javascript' src='https://d3gliviwslgzfo.cloudfront.net/WebRoot/stable/Bundles/hlq-2024-05-08.js'></script><script src='https://d3gliviwslgzfo.cloudfront.net/WebRoot/stable/Bundles/hlqmigrate-2024-05-08.js'></script><script type='text/javascript' src='https://d3gliviwslgzfo.cloudfront.net/WebRoot/stable/Bundles/hlqui-2024-05-08.js'></script><script src='https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/bootstrap/3.4.1/js/bootstrap.min.js'></script><script type='text/javascript'>var higherlogic_crestApi_origin = 'https://api.connectedcommunity.org'</script><script type='text/javascript' src='/HigherLogic/CORS/easyXDM/easyXDM.Min.js'></script><script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/prism.min.js" integrity="sha512-axJX7DJduStuBB8ePC8ryGzacZPr3rdLaIDZitiEgWWk2gsXxEFlm4UW0iNzj2h3wp5mOylgHAzBzM4nRSvTZA==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/plugins/autoloader/prism-autoloader.min.js" integrity="sha512-xCfKr8zIONbip3Q1XG/u5x40hoJ0/DtP1bxyMEi0GWzUFoUffE+Dfw1Br8j55RRt9qG7bGKsh+4tSb1CvFHPSA==" crossorigin="anonymous" referrerpolicy="no-referrer"></script><script type='text/javascript' src='https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/Bundles/Desktop_bundle.min.a15963cc8802bf5ef87ffb22f53b2f3528e2cc6f.hash.js'></script><script type='text/javascript' src='https://cdnjs.cloudflare.com/ajax/libs/html2pdf.js/0.9.2/html2pdf.bundle.min.js'></script><script type='text/javascript' src='https://cdn.jsdelivr.net/npm/instantsearch.js@4.56.11/dist/instantsearch.production.min.js'></script><script type='text/javascript' src='https://cdn.jsdelivr.net/npm/algoliasearch@4.20.0/dist/algoliasearch-lite.umd.js'></script><script type='text/javascript' src='https://use.typekit.net/fho7nrh.js'></script><script type='text/javascript' src='https://use.fortawesome.com/7f3536d6.js'></script><script type='text/javascript' src='https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick.min.js'></script><script type='text/javascript' src='https://cdnjs.cloudflare.com/ajax/libs/jspdf/1.3.2/jspdf.debug.js'></script><script type='text/javascript' src='https://unpkg.com/jspdf-autotable'></script><script type='text/javascript' src='https://use.fortawesome.com/39cff8dc.js'></script><meta property="og:title" content="SITC 2024 Pre-Conference Programs Schedule "><meta property="og:image" content="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates_forweb.png "><script>window.CDN_PATH = 'https://d3uf7shreuzboy.cloudfront.net'</script><script>var filestackUrl = 'https://static.filestackapi.com/filestack-js/3.28.0/filestack.min.js'; var filestackUrlIE11 = 'https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/JavaScript/filestack.ie11.min.js';</script><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-M6VQVS2');</script><meta name="description" content="View the SITC 2024 Pre-Conference Programs schedule." /></head> <body class="bodyBackground sitc24-preconference interior "> <noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-M6VQVS2" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript> <div id="MPOuterMost" class="container full"> <form method="post" action="./sitc24-preconference" onsubmit="javascript:return WebForm_OnSubmit();" id="MasterPageForm" class="form"> <div class="aspNetHidden"> <input type="hidden" name="ScriptManager1_TSM" id="ScriptManager1_TSM" value="" /> <input type="hidden" name="StyleSheetManager1_TSSM" id="StyleSheetManager1_TSSM" value="" /> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="CfDJ8GYwqx9YzLZGmPQ2hZZF70JgtbBATNR7hKkxs6AaTFqCFLmj3YdNAsVp93qOCfD9XTpfIC4PxC+adPNGSZy5VvmUFXf7Dx/G4mxQJaNbjKoqYDEcqeZxCFE86hqOq0VwteFyKYnvJUwrAv86AMsTv+91AaiPXmbUAEtuOXfVpIbN/qvm30L6CFakjzJfjlpIhHMvBPnRJ7/n8eybKsk5D5je6SrmCb0+IHHUmM3+74U6RgD668Yoh6mxvogZi0z5AKGB+SWBhaXVIIbD3KKXrCAYTlOD0M7m0VCeQvuYo+14XKKjncFKABQjQaUsVUyniI8uHYEiikOL5jm6qV6yBdYUiOSGWgtXvpGvURGNDHhDT3qYxPW2QGN5XECbsSQGIfrb0WE0SGptjPA0bZlgJLr2vVBYUrY+oid46Uy7tPMFNmvR6/bKC5uEN7E754+notdAq0EnlN3k+VIZb3l2qvMTAAw9lRLg1z5gjLUB7SCJWHLLjEKd0mE7cucGNIRxmYgCPOl+FzBMt78dyW821FOF9ayb/Yiv3LgS2o9dAhzMlxyONVxwsUIGpecqjai5RmYGrM3zeoqPAXlz4KG/mXyZ8BK12yFl6lDh/FvoiXSzyVd1K+2c5QYWPd13iGExGtO7l4hlaCwBVP5uLnj/GfdhpOG/NdxBY0Ub+EWDexxpAe+Tg5yMXAml1fAB65GLQ7F+jUXGy53oUPkI5bZUtwzV40OByIQktmRvofgdFh3NoEOwyixXBkbLApCaTMuOKbxKo2uXJzaNkuWjxtFfK8mQCU/pGNp0+1wXdl+rdBTKfYzZwNPtqh+tAPy/2dgUmVoeSWKY/TPr6AM/oTbh2WHLHfcq69n4Loh3gEkG1RipyiexbLkniAS5tOTtWVYLCfuQT/9yG/S7Crzv9FUVw39AtgaIbQyOVhm12aT0rjOOEprdAVZfwrphhwLqRabW1aePKQhIVeJCzCp8H9dJuHJo7nqloj/+WH6Vfh6XaorcAl3/GY/dw9T8hyItrDbX6ARt3xAv1d1Z+6t/zEVaKR1EB4OlM3j8t/IH9pvy86nbqHGBPh7l8Zb5UKbBuivLHmQmtXRvwHZ3kMwLphVlcCQScZR73uPZuNupsqClSsIlgubXBRsxt42MrI/moKeYYETGMJJQLa6tGKo6YFR8JitDLmNNLJa7uoLzAKojaI7C2+MRdHikrzg5DFAD4r+Ri6So9eMKznbRfNZBIzI4ZOaEAl6hdeD/bvUtjhKvVIFsACJjO1tuJJA5A3uiCWsShMbRp0RV1T7sCilXL3uPRqzis2Lms+euSkLk332vbYoZ/5l2y6IcWWLQhyzJpWHC4tDfM4PcAxC2yL2VI2mSESkgSQe/MFIK6ln3VDW1VjD/eJbr3rUCVUjqjmsFULyWw5/DGhpmJbWDn8SOVrW610hlgFUfWOuFT68jZWSInYoa0blHmwMlfIZmNuIIBuLqFMOPSVjhBkfKpPELeVrP79oQZUzuR6ky2LYsuj1+pnFtRMm2DlcrvhlkgcwYAH9iVcR/EfDF8bh1dYyHWHwH2itPDXWgVwrCh2URynFvwYOBCt0a+PinjIDNlew5KeOVaZlIP1iSn0O7In8WD5sGgYEu0aBivUkbQzk9zVh45ytj42TecaqCukGlch37eZu2xoa8xakKclB4YdbqYMouKEQPCRVDfhRbc2FBZomSOofVBFvR3OTtToaaXoKYAZIN7Wq9RfZkAM4QDdv8IGUGxhlhU+dBwrYhOTY39S0h5oODPm7HuzD4yasAbjg9DcNBjyWPGsPxQkVAQUBtS++Q9hw4inxJb4+b1v0UpfWfkOXbnarYHU8J4bNIrDsRzyCb9Y2GdKmCHFr0kQ/atyJcX1L/fO/qecNGWImpYNVcBFYtJXsO3ZecVnf/9syv153lmgW3pyqI7FOnk4e+ze+Pe+aNeDl+FgpBjyDklcIAE+EzmZT1Po+P477lPtD3/7r5xzRBtMMzFsKXUKGFcBtzZ/okaNkVMPS8Jx8xUlzndLgNRGdrownUkSzbfPjEE+JFSvwc3SBSWFB0/zQMlD7koEUM0uPYVxZ4jPjxr+vWH09zAnyyouOjIH2/m0bg30OemyQ6mf6tNts1ogCsiDxFpTh8FDWBcvbavfS1VgQxfwiJOyEfdYRjLAHfmnzHucTkfLSJhQEXuWFIwVuZiaX/HOQBY+hXA3cRo4Ac26afEJrsniZMqT8gwFrBHbJ2Y2CTJS/7nma8A6+sFrrJUGn1TvNBP2GIJlEaB73koMJScwM7x7uEm4w+ZxWsuGpTZM24P3NmMdt+ViygZKOo43Ab0dXbeOWVJP4w0Tdl0U33sutjWFaOkflWDde/2f0FNHEeQmSBmLULS1ujxpeNGBrimFjrhcsFWZTdFS9kYvlELu41YwCgmCKUPop/B0QItX7DrKGgtiXKmE9tK3ZZrfeoHeQEoik5xjAGOZDL4JnY2JdQ43faw+cHjBa9XGG3Q5NbJHg5m6XtWa5bFHqgoHhhhegS3kHuVgqnQZpgLeCjxgH7zcWZfrEe/I4zLfJJMSZlgV1sl6MlEy3t2By/V0JCDkRF6uxnPqKGFelyGmzNV0i4iS37FkjzcdcaGGYH1CHroGxB7KJvvPraJPnygXJz6DzZoW7aH2/XPIB7dHL5M6sjDhQifmK6JoThjE4CEnaAHlfGREjZ4Gzts3qjKrYooePCALVuvUchUjsEn8og+IjJwU0AWadxlRLAxsYO+HrjD333U2+1tkjGpajCzoP0RKqvdFLhGTCYNN1uDyxCFmSjq4imlLXnUzj8yNNiaxeqe+eQImVPmDqvwWlr+oBgA/YEblXGUtqdtCMLOurVq4fohpHCP2NoceCqLpPeS08clA8tVshQuviojjB6biMMc3juQhSgj5e4tQzN/qwgp8x2I3+8ZkCExhdlqNxkKBff2P6A0IJ3J3Gn1KKfO+cDki1i7uWYa4mVCfnl5/0TL3CEhBGnaijhHzih2QtpFN1UnCapYla2858ezJtCI6RbBRT0VqrTzDUM7oW8sl7DVUGJwfMXjEJrdS7sK1whZoM21C6RZBlJv40Sye2ma6Q2iISYDuLRAaoae9YfvdUl2jb5wo0hKA1eRD94r+CA1Oi2YExxyp6VS2K89IA6Tbj1cV0HBWN8yeodn90HBJeVLCHbE44X5lqgdwjftecOoi/YQjUztC5nttx6xVkWnhxW+VU6HBKwNo9FoGWrdbcyUKdY+t63y+1vZ6A9gC7BuB7/NqZZIoibSFOUM8of2QIWA2HAq5ruNFHWtgHbJjiLZv91WpiEEgK/RI/0WM3BjY9IoNvZuKIHOKL7T4YgwyprZe5mlMUUmGjrJjZL7Ibs3F4aprO0v+9apQzlAQJT8KwMU3AuS0OfOHYritAso06W14nr3L9WzupWdZOCtyzS36jxphlPE0OfhOJqYKVpFoIRKfKPTKU+0DWK8b9Z+6lIUmyE/xqK6GzV/pPpbn0jlE73F7hccFhcTPXSQT6MO2LpL9Wv2xZHDkOlp2LDUV8rX4MXMV6CURJQB1u06vPmZfmLdggtLRjelrb3nVrl4xyfiaQV3Fl8EX5ACdehLHYrIKwld5OjgAuYb9VnfuxpElLeclAj3XxITqH3fMgmuRYjkhJmp6rRKbSRTJxPW3jHbWFwxzviVZDt6p8tvH3qIQsSUuQIIr8Y5i8wBYhTwT7CfutPjWOYhYXQhbDTrIXv/zgOyphRmovgm8YFB36i7UNd8nKvWsSmcwQN9mWYvtxxCyXly+zNXBNgxv3ZsdPi31qarv34fHKiqJUSJO0Ro1LwDA7xlWOVp5fswK+podSaaY1zpNCpx7zIZ27o7Sfj7KesPbzo4VSE4Xx8n6DD0j+F/XuQoYEr4sPXKmUdsqy5yovmyXzg/QlMRXPZV4xxmJ8oXlW2evYiUEsmATASizxy/bPeOvJWSzHEXQc7cBlfYqUWQnztZYNFOY149CNxzCZNbHGgFjn/O79zu20jIYh3hv0PiJkf7Ke/sP1CHGeXYtZLAOk8iUYwz3Yh1GvsTQJ30WS/TE0M3JPL2OMn+BCgQ6Xffo6xmV1drzbHe0jqaf6IlIR5JNXySqSFo14BO+6YjOHsX/nyKUqPeIoSZOFCiEan5SUngGUfsDfAe7f8+Z3NF19+/njJA+DDkTGUycxPXZXlTBd9dlpOuV+YdH4Pf1ClN8j9ONMJ5ppAyOLKtHD6FE3WUPh4gyvxssArUds2ZbVHkbynzg71YmdQPOm6gdVXJVKJU3exaHWtsI+ig8++FOsOqp3b6U31svazRS1tnEf4My3utZ2vVUmBinoXwAC9WiJjasMNymwVUKeQhOVTLO2RCuZ3ZPbuNzT58/GqaY+mLvRkLk95dY9V0CGX+N0YPJhlHGLT4j/taB30bzBGwc6PXdd5S/0QsSlIWzdJWm8T1ESMjD1seo76ceX7/XNUEOWFwvlKMLpmHh0a85mY5vOJ6NTo2KObtfSuYBBbZzhZ0sIBdxLCK5R+gK2frX46z+POT4549s63rYNEWGVDpFbEMF6LUvayZXCbV3NdUkqYybBcO3DcfcJxGWJu6tS2nhxHSpZgfXnkJ00N5XGr3bLp0gK4evvmGte4WmAQ77NtzyjKTjI0LA/PuzMCqKXthtLM38cMFcYxvcT4RTbRk1bZnEyS5SjzlptnqxwcjeKnzPzpAjIiM9+JWwt9A1zoeqpGdCsF7ws5I8YY81UHA/SJAESwcdXACBUOFI4NFKycEyiAZMG8Bsdl8sCrBLJSmIdN9eP5M9TYWJislKxi89gagCfewr2hejQCammO9AiqSma4805tr/SeYJVZ2Iql8gLx0bbYuK0obpe9+GGS0qb2Nrt5XSvXik+1VEdhTb06SoH5T9SAHQk6/0NUbV2PHJUiIhMWbWAaz92qOsONH9I2wtsH99JIXGeFIjVnOpq5uweLQFKGnRQyU/Ppg1Ku/Rj+cKU0oTpYtwzfLJwDujeQ9tezVi6XCcq6SQ8qEimbHFDDEYw2L06CEwZrExtZ/1WrHIwFExW4H7T79cz4ObRiDiAWeH1phsG0z41iqzaTzjH4uB733UIJ5mxHHCafSKUFaDWb+prw9qzyGr53ULXnrPu3lslxVTYAmF0ZF1ZeTUVrcpJO5cNNFRmASFvcFJLjkGQ3/6WfN5imcBhREqjMNOrNusogBSWVAzEGso6TM/6iQ2xpQw0BlU00gkQhltJC3ypopThFGeb7GF7OvpiOdmNKt7rhUnLCJGcc3xfgtggRV+Vdh8aF5aD+o/5q+DTrDa7sQPCOlGA2X4SLjH13Wzu4hnds1NqtZKTqJgFnwCxScorVf7XmekCLJhMktrY7S9MEeC68F3tCf2RzgM9uutAnczbDF0H7plhe6uT5Hqo+1aVTC6fVroMbHXqg1a1G38RiEjmjhaadcwUtbSProVhIrvRTtX0HZIoTnOaEYjftT3KPtFznjCQQmU+LGvEIYJBCoEmns5VFpgJk5fekl3eepTGGnc4ejxU1fCUXT/xByVLqnhLPztDr5NVdHGgNFlsRlrK3i+ID6sMV6ZOyfh/l03vgzm9Y/xik37rc60M08RQVWbdihNZgfroFda7G/tuqO+aeB0vVZM6O9BWUi7/AmxN03G6LvzUx6Aq9yHpdi7eBdRjRP1U52d5ARk08pKvnRf3KE/t1XkQBwnsPcZALXC0Nqfj/vvqFvA88R68mD692GY3CAKoDccIYIJFku9nXTC5jktbxW6XHH/39SAlGbDCegdDSRtn61v+J01kjHuUql/9VoMIm5FdiWUaIxhvcuLpDNqJWbNoki8Wc3uL7KSu8DAnpEq0we7p2jQs6ZNBWlXTuy8pdg2xgFvpJnLUh59nzttfEHLZznzmaVFHMr/MLtaXk5rxpF2m52EU9V9l1NCbWvG7/YFwmizzbyxua2zqJ0uf4fpisHkZwFStju2qLEJ8hu5/wFfRb+5Ibe3k7ZLnZYOw0mXko2zp8y0K44OYasR/AqGguwndWKQNYjpWYlUCutbaH9tOhNpn3+Y68rttrqWom133TalyMpRJ01zliTRfndDWiMzek69S6lhMQSTS927R2LADHrJqxP+XQvmX+P4W9CPyYKmDqKduWT9UyaniuvQkkT0N4zomzPIO8vEIoBXTK4ODrjTfmMgevV+VD2HchLryF4NqH2NrRcVey1NcD5oaYLgvDqJVm3m4QEVl0rq/nVtETU3gQdRpg48sWvx6IGVIZB2oiHpzx1top/w5ObOc7m2PnVafB26jtTKwmBFDM8UcreQKJcg/LlBaNxea+d5Yj77vnNuySj9afhtv/JC04Ay/pCTWw0KFN+SigpweohY4hXdDP/AmjyD7Z0qsR4y7i4ulQfR0zy6uL/3ggGuFnoY/pps/48fDkQBxB9Hbv/uZEhANudcT30yZh6SR9nhoKLQPkZGWIAITIaOctnGKNrohhQn5JopXIUwQpD8rA0JT8hOvCYbEcpO9sOteFTwkxImY/1E/s1LSHdiwJyB2FomoVF8Ss9YokzMJUuvlykl9T12ZXg7WUJjPtd58yRAAypCWKEZN8qAO1xlqMScC61EMmG601CxUZwXvM+Zd68zwJS+rqEs7uBnQujA1TMt6hlnYDeJchxcxP4QsY6I5PZKB3NB4TPbfw6O6+m1ZlztiIfZ4Zj3UW5DD3FqGu+6LEnPJw4Df18oKgTRSgMxpZkEY2wtxG//qDwgejY9y1xFLQteoc6Bwwd5B2uEJjN0R6iY5UBl3ZUxHW3F+97NNhGIGagRXs5lYbmbnO/SQoarrLj7Yx208jdOumO71pSXx/6Ab65TKw1Y8Ddk+4y+/+YtrGiGR0OGbIjun/xQQDlcVhlQ/bKwbwNQoxtc/HfEKXTwrN52qhhy0bYeUihsMRnyzB0QLesqLsJie5zIxiDCxsZRYhkMDascs/z26SAYPqEm75lHXC8JhcABYCRIHzO3hk5ovzrhfslQ0X5XB+EzON0TdTQPG1027vtl49C8tXzbLLj/IlSXAtLdYuhU/oplcwDh3hgvlj7V0uSBP3aNMiIZhxA2cMU0AWgqoa8l0Hw95RJ/4LHuuOlgp3U+gaQrx5mYnWSxcIIgx9wVXI4qWOfECueEMP1PUaNIf5ZD0R+H9zux27Bs8eXG1aq2HFU7GRczndpv7HtycItOko3qzFSUkg3zAkz2jZ6QAtAszKfVwrm1gmoqn13rCJbDryGrDtcWBPwqpTDxGPJFkbh8revXOA8bmZciEVMNF02Je4R2PuEHc7nyQg/zXE3VClkfgsVpKIvNnhzb0XWFzXZuAq+bBXly86tqXG2KQqlSIoSKl9sFqCLm6B0TI/x9KkRXIqZIYLg4t9MlCCPnfgMA5fMcL0TnlqRWdkvJt6sreTFwsVXtqX+gMKzSACcIrUAyVaeZ6YT+JYiRHLqoUDg1oKgmtQHODr438qzk4M2QVKQPBKmH25OVGoNGOD+URH1CKCzjN6XGKhpAV1AonrQ8CrPbWcMXUSYU3sLOs1ocAstsH6uvk62F6YlwWHhmfzmB99I9aGYQ1Cebt/3bCLfGI9CmvFUzZoD+cd6Pr6jFRuzmQe4/an/xSWio0Yt6Yk5KF7+TqU5CctUk/sIhmYBTvn+AlYt6D2r/WAXVwgTShEpr3gUJr2Yh9IHRWVposDjdi4MiDIWExza3hLcfYK467/UQeYpg/r/YcKweQZhsqsbuG3mJ9+RCzTibS67SwKA3lZqfzfBCN8JsKW9n5nUoeABg3HKZaNEhsk3OCiTmvw+2YWVA34hGlaD6a+TMq08o5l6faCvPS+Vz5UZ7jUtwX3SfKLpGkt/ROtKrbXbw5ZPub7+sQBJ2LurZt7OFb7ZjUbt2azKWajKmZetzkSD4GV8Rx02Glyw0F5Fyrd0tGR7wUk+v0t4dMhruYFIORJImeJprocNNH948d1FVwEYOIanHns6fUTb3dYjaoi+hsg+gDuxWXVd4Wtzg4JeCgfqmUpzg9/RRSUIW0CuetQ307sPURNlho4Ff8EAKT9S4lpFnYGJrk1OKoELH6fUkK/dqCLzJJy6MPzbrzcijCQd62ElSLG/D8PRpQnClZnKiUGOcif2qcPprK0TSWBMS5IaWHJzGYoLvKvTNRLOj/HrfH+SRN7xj1SES+yeDCeZKgI6GAsvH5naijacy10ajuS7KzdUk16GaFBRCCj7t5DVZiVNgbomM1ZUYAS2BT+nPTWopMwSXQpXiP3TgaFXlH+T+G2hXHVl1g/CFulpnStSo5iPNfCyxm40T8H4HYXd9BPGP6c5bAZ+OhXYsvDpYVNVHM2Br5/w6yG51SZ9EP4fXnyJtX0dzx3Qd++OQjqaLCRfk0e2SSO5fOhMAKs4Y0MpZZfXivkjGzgCas6b4t0ULUdF9DVie4q/3txJIIy5ZkFVSNyqvCU2tNUseuDHIVVaC5MxiOBR1SZT9zAmh/ycXiaVSaEQmzJmVgZUx/xXR4Osc1QdbdoTOMek0yTm/CqcASqAEUoWusjARth/jHNXA3Uw63cbD6IUrh8akEjtXgqwMwM+ICrV/S2ZyfGzirhf/cMgqmIWpYUurhfamS/dQiuP3O+Xp1tn/QKfltZmycqSvVnuIu7EyrCiYaUV5woNLvDNBULf8gduBSEgWVkeSWs5ySmDxJFVHLgPatf2QumW5KjGxNdXCxk2na48hiie1KRdsQKi3wh7FLcGxDTQHIFzv6XVQJq97oBDJxp4yrmgyyGUIVTKeUwojS91NmADFRNevGtF1LENSjE+Rt8vIXLPhMNsmWzNJLS61p8pApwOsA6k+Uzberax/sbdmfBmcdn39ssigv0cjXq2uilM7LJRWTFtMw+BRLy7GRT7BTJEGzW+ZTN78MLjdDF/4yWw0DqwpQ5yKmYAsvGHC4C4P41YcuFG1XT0TREQBzux7JDbRPCDOX7L0HZIOQ5Lsn4tt/xd/wd+jIoNawoY/Wg/LbQSR4fhcpzO2JVPymvErIhiSrcy5oF2iIuRrmZGbo2w2meWutqzYh0wSHt1VVdj7JV7PU6quoT1a7NXD4V2Gy2WonA+g7nX3Dqcm59uWGTCALie2MUhfDhcxLqudBCejUOFZyKD7ydcL97cMvQkZGACN2X0nAf5CYTbBQ61zgiFN6YEVR32le7sLv48Q3iRQVuGhXp0MevUsT/Tk88y7JPyDWU1+gnnBttechXQn0kMxwutKboGKoUnPJXUAUFmrVIFqBq4HI0hBcmyMPI1tMn7SM8rGjb6m2XPqNZ736UYnCQcbKuLg7KgIyMlOqaqNvyvM4LzBVLcHNDhNRjpj8uom2JwAY1001CU2cQP13nuyxsy6JXjcN9BUOLFNKXzmyc/j5mV3EXDXgWk1R6mrTcAGkWXAI1MyXbaHcGxqG2YIWTyOQnqj3wANO+MUbnXRBayNidRWPGLM/8DLwUPB0jmwvPBjsPi+lpEE5doQWt0P0x5bZyYOmGja9hvDMrdWv7fX2dhQ2PsUMgmnaBpMBgpFeqpF94TdicaxipkRpjxEhApmtpQxqbXW2tf6hALjEoMXc6qQ0NQ9oEzpSxKvPimFbYjnE4h43nv+iHs82SwMe2U9+N29mVKUyyrB/A8gLQndOcL6T1ajCQanxTfnw0PyM8h9bOInli+92HB8Ysql6PW/zaFYqapt0XOTedCQAFRgrA6HcP304AmYk/i27ktc+k62JPVdqUX/2J4CLtoAplUjKyOSmgSTU5plRwwG2vWD8kruwfKdoCljLpfXyuehqkTDPvNZXCyKBeqzrnU3eMVbcm5v/6EWd0cFDjVtBOT1RJ0VuNcjmzsWJiaRxxcdDomngAlso8sVGG8p3UKumz2ITZuNdjox9reDOo2BnrcRfd+BZ8pXDnHwJG7MBOlypFa6bXcrNvGQYQc9HWWA2XFZJzFmmB+8tLlhvTmDFoyWQu+ZoqODFWqhNMMAuMqOweSTOYFOix9SaEdbgRWBbE0SM5Yr8HWWdcdbkEt8gfdo7Il5mM0ZDFk7d6hAPcWz3BQJNxo08YRh3EXo4nLu0uwHisA2VgJrfiXCnCEVbjw/VRZVBzu0YM6LvAj5H2l1sIg1ixUxh7H103qDGDph/Vi2/hJoKJm+JaQLp+/nsBn57M60qv9YEtwwCp9a3+I2AHa+GADR8XGDNZx4TNscMZARJm7vbV4zvT5PIK9mvLiPjY2R96tCsmz3o9enXp5a2h6191uWe+q2mW571DJa1bCnFWfBhKisigIz6OrTXx9fmliV+eKaAy17uix5TmrJObscSDXQGqipSpL+JMBnY2tV9LgSUjBJPExwCU2kWLVP1+iQIgSVgK1Q/vz9feJpZlqTooN6MzVb7p5laCu9QHVBNDtT+6x4R482LfWwCq4LBk/0nj4GxMbEGlOIBOZ/7M3rCY2I9BkSeUuLstF1lBWMAQPwdTz5NCfXEFDInEi3kw3fXmlnuCNE0R8mjXTR4AZc6E5zlwSg8Wglb5n/HjCWR87/NtDQ86JZcFtWTv5dcTnhhz6OOtpifL/9AaJ2CHiOCbOkiukRlZ/Sj8b593TYMC92Pywy/XKW7GZC6p1M9a4hPp43SJ6fp0N4j+JaTmHXZXNiYxbPqCIafpDvKv1I7R/xBQ+1blFpTtYLPObd5BLTREOT4Wvh6BCZbfpV5kV4+tT2VMHPgpzKmr1NH/iaMDSAJZ2f6vaX0PTmW6Irxz5Mu7mXvFE7K+S4EatkoThmDq7atXhpAtITpBQscjzVqvHxgvLcY/FxtJAhTCBU2dh562h2n/ER2wRN9LoCNKHh1zV/xvosmZHjlHAf+Sn5KJlZMWs8FwNsOgnDpye6NFHMBOOc/0P9FSx8BCsA4yR59jjbfYr3bjw6Jpy21+xjinpJ6dAWpjJzbhwmdi7NmYMlQ8rU6Kd6/9gLwvKuVQ8y7ssCoBPN4iUVNcoweBNas284MpVOZ2uZClMbZBZWqXiA/lTCnRmFerK+hE0Iw+CKAnZGyYoh157W120aDLy3sY1OqWc+GeLgMMoe0qXjV7fQmvAbl7WGAFSYJEX7krXf+AWxnWfH5S1nfHKFbcRC2x4QHPQne1qKTz517gmH34j0gk0AIxfbTtBditHNAjucQWeOq5clhcj9WjXH+YnZXXGL7EJjcjZYYK2OJKT5TekyK5nE2+zDuQG8j/tOviAe3ypsC0Y+zjt5aF+Q0DdyXYj+dJC/1v1Mhngty43/g3LIJJufgVHvCdU3FnuJHlgVZUWhJWA4SOCwwQ55Q3gxXo7ao2jeLiPJBiDePbqx3dhf7DdLc6Yo+kyNqzsMkuuYxIDQ8rDzt2TWrEOBfuGiRLH0gkruTiv4JWSc2byR/NansanCIMFoCq6xgxZCRVL5PSf3yg/93N3LoSxQ/WNU54eNK6zrhiGDbceJtYVgmqIQOi2rBLO6iCVMANfDIe2mqcg0cJediR/HiXg+1bQoTsDIND/lBS7hdfCR6o7VjJSyYBVUkSxw+dFnUirkh2fkArloHv80tvC6EXX1NEtsGRWloBB1ZaVzV/+1JGVRKJSYWrXbkWoURkk44ZlYJ6uvP0p0OMzxVtVZulO/8c4mWigKh7UIWJ1DKC2FFwiUklqyFGoIiBLAgy2FNIWwJLmTyqKk4DoxmYlFBivxHZ+fG9dgDJ49KcKdPb2BEgONrKsesI21oiz6haAQODDLStcyO6GVw3tv5jlCWrw33wx1XwOx8CxVgjFjPDX4naWnRcfT8plMlXOxnrh6q/qupbYEkZRK8Q7B+KpmOZ+2X2LAM+/8HrQvkQdnx4Cm7lLu2qmqar4aFUmQq9rsFgkHvVfltpcAYZPNCegbiCpiOvb25MwCJGUlV7R107Ti1g+mmDD7advCl5ccGWs12PPpd2LrRgPwnyeNE8VPL8r3KEeFVFGWK27Wbq3LPlcdfmBkflBuZP/B4QC+16Wt2XOa+tzbbYwFbYkVpXrTFDKN1PF0++4FFu9EXv1zT7r2hp6ZKxWJCYi/Wz4gj1TO7Ap+2ldZ31pb8TaOJk9kzZikar52++V5pWl9LeFG+D+I/wQ8uaho+GZUTmHeANn7xf2F7+o56bYaXp4dZ60suXf6iw4tvQaFRggekDCrVyWuqqLXJuLMiIlW3Rovr71rzIy14HDRthc+x/kc5Ci3AqfT0742tfspvBhZ4nc6B1UvW3V6cVTdpTWpAUHlu8tCtsXhsohLak1s4w0xSsvzaDVCGHdfNp015TSN8XGSzsW1kEZeC9sDffeTQfD8XNLi8r4/laUM98En2vfj6kwozS6Zub4FtUqqlCaf2qIy+cM2h0+WZe/LK44hK0P+cJvfLPDu/qruHO51KvOiuvurdHrPjPgYPKMdQmjXICryj+dF0C80yFEEwKxzQhOspc0N7eEfLD9FM5iI0gTWHHjQ91leo0VJBkRFhX8CAVkBMXKFn1EpTygWO4Gi/wjyh9JFAGUA9xgSWamNIU+4jFj1o3hZwmToHrdqA9D56YI4lEGK6AI7jtTw4RwoOXMR1C5eweg65az/yfI2WCrDI9eqHcAs5yZyyN4iui0V7F4tTd7kwSXNkVDZAnEb3hvZ2d/NnCZrTyPZ1iKD54v4Qq3e9bUJR2c8zleatli5ERNL9W72+k83wo3w/LXFswQzhq5th7HhKCezBtGkNIsmXb8hmuXpMIUQNs46dOc84ltzY9GTuvWJZBvEuruxARsGmDxPB/TJUmiQ3xUxnzf8nWuRsNNEQuhYrGyISKbIiGAk/ro81x8TxUNZYGbS0cL/F+zN+fW4tR2u6FN3rvyDvk2/Q0OD3th1EqKKVFEJjrTrUh51eslX9Q0hVHDl4F++oABIapPhTTPY7fFwmp8Xw614IjpV8iiW0qxzmrmCOzcIy71EPIUq93CVFA489+ZmvNC19lG/hw9VzCs39/Jg19ISj9MOutGtITJ9nSYWO3hszrccP4a7yA5+9Ueqjegv+U3hAcPqI82aD30dylBFfROlOURYQqujHktVi+hi24HaSDxVl0X8IFWUtPnjul+GyhM6lv49UePkWU9CuZMrRh3AJjQ1Y31DzMM2hMJpm5g0SW34VqEImUW4AlGs5krPWcD99AJMUdUXCrT3Uls08MVQ48DSjmt98kkg6ISCrnywyZ9uFpNiSYwglCJ0fQ2/QPRSPJnomioGIToNghYj6LmPeI3F2ALLAGDPGjIGO5SVHZf17wbtrWGXA/8RuvA0hwYfwUZ/0baJQVKIhCJILoTO70R+vFDdghahp+ryVSafn+zn2Pn8WrB6pyiIV3HWejz+TdXI9czNWOlUMh1W09S/KTzOst+eZ1Z8Av6cohMh/YFlSrglcXnCl8qhpBnYIawhnDUuci59I25Gxb+CDJZP2ycnFizGt87Ui+ujBMrmCaJkE55He63YncfANKuXcTlHbSWl+sRcaQPq+/OuXMw+h9/jaJ9PZecEslVvxwScceQcvHBHGBObni7zc8P0Pu4hPk3JQM5M5Zn5q9jfqBlaw8oRJi2Zba9icD3lV/XgGzs1TJN7ts0WrC8oY5i8if5+WsNT6+rUCkVdfF0Up0tMXchm91wkWLJ8yYwmFmJs0fzlyLTXv3eWUqHIhDZ4KH0DNNf7iOrWqQ3dNyiESw5Uk3EKBWZsYmjs4qIEIwnSqKZMUx6KBFx5mVon53fKf+YqC8mMPdXn/GSMB3KvKixGEEThT4IA08/73cNK5nUiN1qHqc91yMq6Il1CY3Z+CrqNFLYY9ZpTNKP6Y/zeclgQ6cP7kFRd7CnQSDvB6ZuIxPbwOF4Aiqlx59i6PSlU3GHem74VSZUchnuBr6h1FFgTSqbLwDBfiJOM5fg3WWRNCjkeedUoVWkhIw4RlONe7aeXCF6Wgt8ZWBYmRaYS+vgT7mYfbrZP7yyKFB85Ru+sND2yObfeh1BsrCs1xERdPPXHpiGS6vzfZNXcV+1cnhiQAQoYcORw4zp+/c3N9qJ6MkQcL8TpzypaEACPVlSup2F7lec8KgQBu4d+7fEG9lsq+QwcbnNqk4TG5pmWLiIQ4ktQrGNa6IpRv6M5JM9XQOBaQY/5SRRHM4zlVKEUmarb+m+DvVzCb0XFk0ruZAb1qH+ttnlvsJKN24xyH2txXia1Uy77JjwAJb6esfOIAxNmlTglWljvAUi8VoEBaNouQ9wdrCmf3VOH6CN2uWjTmbx4FYaqytgpLy79dNHTOsQFGLAg6lr2eaPmUnbIyk7fGbi13U78SH9BIOjvaAWIkRfAlLNxsmGObgfPfGvJbyvdSA4bLIcNKeyDu1TSEcJtUzjkAg+UL3UpbSEWvje7bwjasx8eKZ1NAdPp0OGUyvnRPBOlkip/zkFQhnHqm4qRin1VOIFR8ZO/cH8qaex4IF7EBwsy2oFhz2AMNrgwv0zOi1ktE58LkPL2m6Etion3Ryu+jwSKvdEwUjqid2tH1G/JrAJW3wOoU9GVpd7M7NSrBfKb8GVoLHVnCWx4l5ftnbSt4sd5Kp4paj2zRhvMg3d2bfY3/UpeAkcwh0FUCfx/yiF0sKV3sTgtbuQHRt0j3Y/a0t+Dq6cIl4e4nhIIrOgKDmgd3mR5jE5CqGxQp4/cXWh/UEPCdeID7C18l+S9iEQFOzyYllmaHT4bAlCCLaxvHH2x3QCWRQG0157B/dyeD5Gy4Vm9lvQ/j0MKf14oO13FkeEYTnZWT24tVPt68yoERf844Ur6KOvSAaDOy7jI/RjHNYpvuhFClW1EOVvP+olN7B2b0f5ASNlSni01u+vXL8m0KF+ai8CXzwgRp2vaTGbnE0tbkSfTkcNQWdQ64Vv94Xpp6JKZcif9v3+SeHEpXAFivJIqeopYRDBsLtHcn2ILn7SnsCOrx50tX2ip4w7Zjl2j1EK4jq2VP23nY0qJjS269f8Rfpi4kV0MXx8KgF/k/AbgqYdSIXXZrG2tLYUJX+vE9C2mVLJXqWQiiV8jib5Re46AqRU5d65cZwmVYmfXl6t0ACtsTZ77bcpbs/Ugl4ApdF9WcNdrEZz4EMe9WrC7fqo+IxyjCDwcZn/OTO+zerHOPfpUHLa50L4ScX8O3G9d/WrBAxflEcdaaObIvnIEVR1jpNRoyQasmnsuOV0p0uQHRxdX9DaICkf15gbGoDpKtvtfQ/fj7uQPiy1/Yxs8EkLV2G8CeiAwXiJviRBnr23zwMhQOcW5cpNcCatHfcgtmagm7vHK5FgjyVeNihm8iTgP1PPvARM3gj4jwpKD/zwuXoAaLI1HC/ZabslLmbWeclnstHxpqjG1q468KefbkLf2x4wDUCNv9YaoTeINXzkfIlrBTqCWJR4PjiVElHmCMKLJ5M6GuFRMumPXKyrAi+3jaWOfehyy6cjgSJXEXIaKPUi8fhGtNFypR8W25gUXOFhnNqPNYLpOs3N9tdDsBKRDnO8TtS2R64ZxSj4Ftv/7rANBHu+7W4bQ1FY3/O8AjqJd0GymY8Cxl5NzzQfKUhnqz3HSk5A5sfsApoDIKVrlLfGlvPKhbFyHA+r0xxWvtHR2MxxSVByo8ZGDLoZ8/BYLOJ6zx5YVXhWiEnCx8kDAqnxki+N9u6pjmULQQ3OUT/Ba5ZNc8Uu9diUyj7zpVqDtS9DIgJSHrN5aO89rnZpTobyPBx0C7WeOE5ih+KFb8WXjyVM8TIXB3JAGmcpP/fQAMHDk7BlGA6x1UK3UPKDiLzIaIBqtDh2kSZ8hmwdeY/Ll6Tjt8d3ypsq4VDQbx2pCvmTGe3zARyOcJTdR6ybXlIEJ8VJa8Z+s98ZqkZGlxWFOxfYfEWsjmC9WtQGp1LGUHKHxCq2Uu+eDK4eYYhe6ETbgu1v1d2GV/Q8bdEwnAJAVoB6b56xXF1LTBl05TcGtOZsnSS6TCcJnZIZqV81MF/OUlTnY9hdXjF1i6Zp9jW47cpf9D3X91xpQ686hCtgK1tui4ezgGCGOt26m/mGEq5Usr/sP9ZytER7URYoiAoQsVjOIZQaA1KmyM3VxWEeAbv7VSWaazYP53CxEj5K9RHLbVH4+yQjt9vuzPA3olKIycEekyaMZQI5qTEu7oRE+Xdn+b0cvY7Jn/s3brXHsGUrFmaS47QYllta/yp4r/ZRW5Hg34ftFu236BWNFYYYe+rmcGcf8ad8FepA9OII1zxebQGNCumud+sft3rt7vp0Y6CRMk9l5NCwZ9WHP7ShEkJboHBpfEVGwvg9wVPil3oD9ebUBPdCse8iE53kgVt/twvj9oICzlO3aaloFfMWOkGFPyhXA1S46CGKJ98c+w9qOx/aS2foVAwDiiby+vF2loBH9WYIN900uPzvYNnMusKNjvV+fL3gyugWfWBDgZHunoYhOMrOjuWtsFfFXDkmBZAjVh1yTGq0Yfsc3ZqMrVwwr6NwAl+gDWM/u8kQ33D9INFB0Dd0hF08J+nO5aPZpPFB+MkmQGcuHUHWbGVMF8tjg39hkuJvf4KDXWhmjrNeVMZn1x3z3e2CCk4ejIBsKn2U3uPm0T0vXUVaLoNGRDqTa0F/xSPOqP9E5h7wLLbogJ0kpj7ITR44dQLDK2vc2UxT4gCKDviov6qyWHJVeyM5akYGVdxmzVuo8NrdL1FcTrR2NhVosaw0Rbi3DAp5A4UaMXR6/JrZuPD1EiOBose2RK52icuZPRFRlBOfVcg8PJbyABWan+2GUFlVpUKCM03B19c8vPhVpCUYNX4MTe8F06qBIjmVdVtnSpDUELMep6n2BoxJFt4Qbadsub9R1RTirKWp0l5Lp08LBa2bmcEmiB+LyFjLSDZ5AOQWETjgTDLhx5O1Nj6K2n7FH8zD2b8+aGfdbIIAoaQYGeGClExPSX79xEdtsfzwSexvuWYZdOtLZNgXI7Cw1261dEpaSimbW7IMEw39zim/oY8o5urWWykt0Uv8Zx12PYimAgxE0iD3FrLXnv8zrm05mxOjGFgcuEqjScMkQ/N/zmRzHxek1JLVz1E8bpz8kUHPXKfSlqLiy1OZnT7Rkc+/HZ6gNdyM6qfXTOvytzGBMxbVv4MrTNyc4JCS3/MAt4pB0LrtG6bXsnQsvjERPAlnXVMxXodz1dfGznH96ECEQ0kpHRjShut99eyzV+SXsR+NyF4oHYrr3SNH7s5ChuRhRZ2AC/lkMaDk7p7W65iRoAsTq7p0xa3136b/uuzPOvYhwjaKhlkJXrOw8w5If+aTu4BH2S5miFSIOmbytAXMrS1oegTOwEMqI0uA49HicaoWu+lXudX7tp0DXcsCXZ+7Qgg/O/MUP+th+st6I7ATuat/6xpqzyhxT6H5Im11klzhOpqVeRxyuw5oA9sZ0Kvf0SuSxehsmNJcybIJsEoRcXXDYJ5mLRSlfsx5Kxhsb41/80C4tuf550itp4SE45oc72RzEINj++0m84hhgLf4/Zdo9qLZ3amqnhP4g5U/3S+IWMc8KU24qtJhhnA/yXdRUUdXMKhk6zoA2h5pgHkQ6NU1xKWiILVJ9QXZCOLECqTFaYlOYTa5Kyjvs9mv2eBVMrVuNUj8HXF/wSw2pR6gLG6R287429SJAL3PBDBckkF9F9i/TyR7vantPW3OXDXF/mjSEPTJs5pTO7eRKMdYqZCjVUwdDP+iNLGWyDDYGoMAEMD8mS4X627mOzXjmccG4SOkY+K5Hj618EfCcZgDySOH9lzfnNzkDhvaCzEy2hEInU4h1u/M/lcmBMX96ZFN6oefLvnLbE1Xi/KdRLPAvZc4rnSMfUjtcPAysppOjj7o/lDtNvsmRgDDMp20fEAZgAxGBzf3GlqL/wBvo0t+hA9z/lxQNL3zbN7tJ3TNzSyJT+pVon/NXp5qENYEL/yxIOql53NnC02rzGEs8lgtHEN4A9ZNphsJz1RbecS6j25x+I+tCtcsLtq7XEDU4RceYBZsj1EcUJBeipng6qCiGkLKC2u3FoTsZw6Bqx8YdCpK/WC/9R2mUjKj7j13Pn45Z4tZT4TorLh9I/ZVqMxaNGHHLI/8B9K4zq7CxycvqeBb3SNhfIfEp40mGuYnHMlBbz8PinBlSjVWaHZsl8SRchFTXhAJg92bfOSVHqRarLXpvVXxqXPAda9VYpR4IWDzWyXcH3fkReNbb2InrYP0J9e2Kt3pPVcccvt74tAPqrvBtatxp+OSUYtBCsvpoguxwUaEv5scCyGt8mq0uX98H7VBC9J1qcJAcdaoxqtUoXYK/pfc3mGJvS7FGvv7fb6Vf8Twf3Um/OkEb+q77ncv/95JdvNG+ZEYD7FHWFIW9aXEl0cmLMqPi/6BiAssoHwnsyO71U1oNgZLhNXk3iUFCNpq72k1YYjrw6G1etPFTgTYLwgemWAIEIuRH2SFhQgbvZW9xun7i+CdiSiOzuQdBuHGE0h6irJiCiXChHMrJppYAMpVYBxcmXt0GYZmwmH593Meg2RwSMEcdCd+Y/pAkyMc2PuZcf2cxryFfr3zoOQNzdd7k2Lq3j6PIxH2Q+y3jvLYI5gW5727Oca21B4c8uzh4O+xcD7R9pmbyqBO1D6muAHVRJ9nMKnmiSV7HBUFiKOrFntyX8SGyyG/87gylJvnwG3uFWziCCwae+6YWy6t+W0KCrL9XZmE9FpYrmfskLHSga1nVCtW8Hea7yEEmI7ori5lz6fCe0AhlykznIHjNJ9/PzLGscwJM5q8nqeDENGm4Rxpl+gkn1T8mKsR2RoSRfwQewwEh/RUdoo9UA75iSB9Hkn5hAJ9buCGFZjyNHIioPL2hreoO3/DcBDBSYiibFGYrs5DdTB7ILqrAc3pv/Gx/SmOwVRW1svulDWqpixKPjzpwrMqjxu2MESgCzO9K9hy7LU48InryFnKPZoMjmbSxSkjwS3Wru7LNohMyGc/A4fHOQVGg5JUnKLMQWqEts30vnWsmlBDFNv5uHsa3QX88K9JhS7c7Oyrt6wL2HtrAY20S1CvPx8M+dtZSH8WNaQkJgm6R8nO655HoV4IsZLpEO1mSot7tC6p4+vyxnVcLoOpd85Zi2vGzS4kGhaRgDaXV1CiF9dE5ZypEG5Dj4JhVnRCek/NdD0etxHWPHErBkZUXojOXOlGPPcwunWS9AkWxgBM6nxLhLQ0Yt4kSMx7SbC1JcQK9oxV5eW15fUkNlakkJVuzEWBvGKAXnNOF7C4qta/HfjwouUSrXeoDJQbdNLUtbrteuo5AzwJKYVkApAs+Plhv+IvvgWs2ZwtEFpOwhD9QTduy6OFzSs+WebV14tebx+hsJnM/1OdxtnDRMk7xnUan/RygdS7yz0azPel4SBpGgwBHmQkA8iwVwNHhd33hTXbYzt5NzRXUpU1OwZnm/EsNVWSVPnHezWWk1vuD5qIFllxlHcJd+VcKv7aHzSA1SBgZgmxfyVHzcq4Q6/ZzGmrcO3CO4jB5JFwjzcSb69xb7IhTDt3/kEZ4MwsFagn2W0F1jK5EDnbXRUI0KeXJQ7P2KhIr9P72TerV2vnRL5TucjwE9w8mSimxMcThIfmqyB6HeK0Dxa7/LVW0yftoI1A7NNvIiiToCtPopKx370yYR0a7GRdXNhtPe9O7cY58nccR+1jwXM4LNPbfiMtlgGaVc/Mai6FlfBfFBtesP+Ax1CrrHj2YA7DHLwqCfK+gBTj1+4riIKkdJ0HtYSgfYqCfih/xuTY4vPA7cFY26hwaCI17MTGdS0p02hDwFBGxRLPORQy4izRXxX2ICkyA4Tm3Ru6AV4N3MOx681SEBVf42fFLfT9DQlwVfiGroJfrD9l8wGUZ6SWxCqbj1df2DnMr9tVZrRLHXp5MvOY8BfW7kc4d74nDrc4YeD7GUM+712J3XaQkHIagaFICe4C3FgGrvSsvwnEXohX+138YLVkvpRPlwsTBoDxuFuR1IdSYEJG74oDTGCZOf2ZNrcRjyPF24B72WvHEtbxXup2Hvh84445N0Gu5ECt52G417WcVz5maLzSYVnUSPL8LWclk7ufxMftD0yve1MKd4vUfbtskLAje6OUN9+SXWKlKA/iaumks49zi8t4qPdyFoD7/D6QIm3u2IdOhZyYdkckDcsnT9L+i70jgnwMr2jl3tBoj/JgrballeMEp0N5l4QiXGZGxtSKNJiKZ9jtSTlpPcHZhmch3+KahUvBoCLYUTG+9azaNv6hk7K0WXeQ/RWxq35bzraD0+J9vhNtMbSbGFha5xPth8FnMP51oTqILnyJz+5FMwHdZ4WH2ifToUdeztiBN8cPqUzgWIDnA23sNs7ArWYzjLh3vKcD0DJW6E5LkhCSHVx3tWiawpHmWoYegWhLzIyMNmwt4HInyDCLARxsAVRHDH+FbzF6a3ksU8wKUOo94yklVtaWnwcqSMHfS8SHyVL0ctsBQcEdwT1yAek1x46CGjDLyBIJKWYxxSqLsM28lu+zmtPcDP/Tb2CyB8oA3szHZxnf50vXCVAJqhYs3xuv2qKFkmnLNhq4w6D9e32CAGBcEEKQ4/gYiV0DCKX5wPdQmJj1UoWJ3yS43JLzJBoUsLl+RgH79hbu6TGNubmQS17VimCAg5EUtrGycEP/v+8uVVf3MC88McBvkxeBub42/t7A3YXbLrxqW7PdvYxLbcDwOZ+/T/cPwnn/DVZtGJhf0Dc6eX+cGDeRyEaWQ+y2hegK1yPKAhiTdWG3+NB+ctLpkO5KOAF5lL0cgTWges20xyL2OVhkT0aoZ8r70hWVigGwmOFJJw66J8pU4vFq5jYSIK5u5Iqgv3aXekzdK5Ymkwkcr8kHMvNF1dI0zO2tyCBKLveNxRpUMmux3JZlnuoPcVuFybvfdNObiQn7ybp8HutE4sFZuNUyDyyAt1wAiPzpBN9kEXk/WukT2CFPaAvnU5FaAb6QAkc6cVyxY20vUMbYWFod620SUC0TuW4kfSgEtKhGqDOmptH04NVAlsCPDjKOHVFjOh7GeUm6QDNYgUxWnzNqteXe8ekxSTNL5VDvAbXFH29ygjufpyJ5Uy+65kEA1MMLLZsd5ucgFL/VpnrB6rbXm2aGv4+RDMjqdGyQw2CPrFvULXM/4cHuTSRp253S0KugFAJ3DgGdiVjZOneKVZVmfRDS+56f38nDQliIo32AnEIxwYVxMXjmLbL3vs2EcvlgwjgBygY8NhPLBGBld6Plpp3J6MRyQyTEQYsPLJKkA+4PzaDiq19aliivqCaQqIPpXYiFuCcQsyfvJ3r1OW45o2FIuSKBC6Lmw3tqC2VSG7pFmN/3jokEL1Df9cycUySDrXrd1xQ+xVuvc/FkHACCh4jxEpXx8JjAr5jemKlv8TVGk6opM16oa1OkxSh0pKy2FlyRYdp912jjVug9r4mA5quI0EbonljuWKxF/rLyj59nvuyuZAXuWEdTyCWbJBfBcdG2nhawAliQe2avP16hPlAe7kteyhTTiRyVx2m3qnt1bAdYW/nB5NFS2klzAlOCuIJTSx/+ZmLuFVBq7Ox5Mi3d6G3X63ZivmDu7N2Ae6lnYtMtpMlzthHa8z9SX/1uN2Z17Ze5CH1f9CYY4eg0IySEiQHYr3fmE4/aeZ0T15OysLL7/ZNPnanyQB+H6LS/YKG1q1awaqmnI2xe+u4RWruTaVSJJ3N+BAjLLp/vAkLNH3aMppgOQLlAV/oMzHiG7Q7U1Qd+hCIY13oKYk/rZep+oCYaJQdJm3j2cszSmLxI6OvwuSCMN1iaBdk8wEEMCQOzQQwPlVoWj4H+KjJggF6vMcLGBGaCiRDmwAOFfU5/+Zm16nH973VgE+dEpAK8t+fryzuN8FuuwO+ER5lY3xp+3YosVl4kp5RA0OQL2cG0l++9bqxHxrZj4F8a3me/Zhn2fCGIj9ZTyv4T531t+nizWnQmMcwUZ62kNuPar3cWxStfrtEVZf5JjKL6dV4ZgnF55ZEmwxMGIV4lu3V+saj0zTiwlD/ojKqIg5uIc3cD+zx6esv+TMGl7Y1CVa228EqW48s0tyuJWdAvlqBSVBEiJejn47J72RV4QssvfSAVddWtoIa75Jfn9U0x0ruvw4+UiD/ORODrXjfI+oNlK2GmnVbeUpaapv13BALm/9AsKFv2ZneqdgAOQeAt2CwZw6VgpCjbvqbRddcqQHLUXSUsRfWNvXIQw6zOww2uX2eAN7VBaQyw158yT5jL2sRDTlR2bLJD8tbOc/l682cMzXN+IP5fWozOkISa7GLqizCj6XXU94tyLPvwW+p9eyHYKsichlvmiH0QL43PevIQ7XgK26CTxqXkANB9O/DdlxC/tR+tjckSblmWNA+VA4OxuSCkrRcWyiRb/KO+PRE2fiPEVDsrmcu8lBt2qvuzSAN+pvrdyyKu//Hwq8PGb5Z8CNs8hXPfVuh5mCWrLpoD1LR94YwyP4bpKiw7woQ+EW2yzA0JvOHNuZ3F+vpQ3QHU8/28YhmLTgBIvDRzZbSyw3ClmjvvXaHwh90SQdlQi3gA15fl8Rrm1tlYNy7Jj9SXbAdWbPmMWF8qP76Dog5CSuDxFGEEnhbGtsHO4Ho+tZbFRi8eL9ZZmWFTqgoU4ocuCEBO52h18WG80ME2DGc3JYnn2EP44N7csQbYdHc3D1NjQG0+ygVhzxc/14W6XRudCx/AB9YxxL/Ot0cbBnoadaW3Iyy2DEQxwwhrev1peCQ4ph3b0wFJgxRxMyjpr/iBpp1AvOpGtT3hKvWeSiH/FPtH9kma9owPPmpTSaaUpgL5SN7FzA5wMOVR9dPLn9BVOaLn3Eyvdw7+RNObORz07jlTZFmPYamNkExuHw1N2LFkRaTwmBfuz/vjRi0qCCyK3T/ST4OH/Hp4+yYZOkLDWk4UGbmiWxBJwUv/AxxTpW8vS8rcuu66WMNNKJKdv/0WworWYHRxi4bQVCdwXkVL3eXp5NhAotfgABhWHxY5SBxe1LJkoLBPMNqlolVtmznLCUPQX0dxT6T8PohrmTgrPW/Ajc4+57vsNZXEutauAOiqTry/nYWAOzgfMiFlkwgCd8lGyaZXNSDqAyf1UrOO+GKZEO+RKejPcCo2XMNte+OMQh9y7NfmgEqgFoUX/I5oGSrRW5qkOLK8/yMyKPkWUR1QM9b00o01EF+c3wd9072yUhz5bZ+rbqe7LmnMTvYhTHdIxzunbToLc1VQsq6UuwQHcb3FPb9uxP9HTMQW0gsaP/F2XUZECkTLljVvjZDvtdm78Tpeg/FUxcyAjHt3v1KKqSTn+1weMy71sFLKhBwqKCcZ38z9H+MqcZfO1ohsf0wkjm9CIjY7jwa/f2gm1b6FmcUJIDjPDtlM/zAUrM4vCNq8OosDYniprgcJO/s2n6ACvcpDlw2YQyye/RSU+k4Ao59cfVxU3szU9KGhA0kUCsBJSBGENvf2gUoMl8gA/lri1vSZnt5fvAKF/ZJMXaSeiqZ+aivdywV+UGBE09qbfU+ajGhIJZ2Ul1GmYIPrulw9tVTti58zmQEyzUZTfMVjq3pz2qOU91B0M3t+MuEWBjeZ16V9rLiQLPSgDTbqvE3Aw4ZNHxrLkXTE+lv91sJzjFDd7UryEt3xCt1JQ9EIRyw5/tpKpx7dfirAj5JhT+TAezwjkuIHbArnHJa0/ylvbMetWp06LmUtwxQsoRMBkfF+A56eI1LWMdMP1RiXr18kCVPUGHsPNJGEPddFgFCoNvHUuCH9fqHAXBJ1ezy+Ruw+ytW5XZ3OPkzuYvYta4sCHiw/jFMdpoWQv5C4eJk2VQAU6bMz3kxTQHC2Gji3/mCetFKG1qRIPTJxvc4SgHHuLblMS4Hf3GIwYAJobwFvt0FJObKw9q7vXrlMgtlyJDp+uvyMRuV9Z6qa5PLgy319CI3OSqpQRRO6WbWdnGRWw0oJ4tzIEGO4bVl/71XXoU1dTajVsdAxnc5gqdtak++n6bimMXMO1sZps1mBB3vWnzQJXkJnJLZpV4GnKeBeWB361PNiUX4qysYPkvOQTT2mkWDW+H8SNzCOHR6oBEPmER98/8CvrU12WOxYaBplCJ6azl58vTOX9b93lfhOviE7e9kU+9SXeePHMwAlDzbRwCyINbKns6RXCxCqL07t8CUxH4sgswb29w3e44wPFbEQrzvZM856OSa+EDHRriT+MENTcN+UQ6OtKTuDY6+oqtOj878pTN4HSRDXVNCMwEgkuPlnG8g8koImhUEDg0BLITF3yAsacH4icV5aZMXmkR1jW/0ItRyV5DY95kkcuJ2P6y06P+eh9/GyeukXNGXsFCIwI0RsA0jFl9N1rQ2SplgL+LDXG1MJmE+SiCOhl9Qaq+bEJyD7dOgt83RHcmFsmNWen8cKhDDxcmby0LrCR0Hx2m23G/1cxIpXopR6+loMgzO6U6ZCaFLJT72lMxybVpNIxktJGpd7ccw8CZN4lG7E75grBgAc3/zcaxi3h1+3S29zXRI7EE4x02yDXGS45yhrT0kqjxLZhoFvrOEOM3DJ3trXX0hXUY2BQQFvTRiqA67GWiShwlDENutL/HkAmqzydui4Y4S2UMYqJ3wVqkUvojDpqxvr4+AyoFUCzMlkYyw+kT7hZvwteVOdEcjaHL1pBekW05blPpxDFnxbdJBwqXl2FoKxYF8LXEhd9hrmkpstJK4KKvY+WUcDzy7SCOao7Gc3wm+87xbNU7E1XSxkmG/h2JJoGcJbQAl9MxRucR6Bm+DJ0ZqoYfvCTXUTEJ9vuEC2ZAYWPcQmsg2o1brLJsdnkuXVumC35/1bQfyqV2RTuYfor8QpDzWp5zfqfnWw9CeNjxPEJcSb6tB7YZ8YmrOgyu48XFqQOxU3ggyopXgS6z0PSkQ121UVOxKYB1MaTKulQIIrMqEWF4C/MpRrGAVf+IBXbSxM49rscVsBs/KCgLZZV8CEAdpvLCy9r4Z+RLHYK6maLZrGtKNgPE7RE+RNd3Ge3TVdPXBNbVzINvc9hF4QzIPIB1YNFpRk0n1GHTZVkj4wfxt3VjXl1bbrsqQ9ajjc0uhw0tkZAKX+pOK535lcC5lXfbKz6qUXfeIPt3GHOsRRHyj9sRZmgXSdlnqISZ3wCk5XnkW4kMIRjv6NdG+7CzgIMCrRQJfCrabQ87jagn0lPLIQaUY6S+clGI2t958W0EQ0LjkJB/O7J7sNwyOT2y/3sS1ku/TJBasXWwbimVfzqJl79BeqP6VuD8byaU/Ds2JAPEw1KWZGyc2+OJxADIs2B9pCkB++gjDT2BylCeoJK2HP1UFA91bwXRPbw1hoYV7tNQQgm/3OgdyabsoMI+bCi78+XEILhLeyrMYWUPlp9N8lwhix6UmwWNjmLSOu8d4KCf25/+Piqv2x2pHTElcomKY25EpZS06HRdCtKcsJfLmJuuo495p0VXaFfc8lhaSCDyDdPQTL5RwDEFhRBPk5/nrhoXMijPJlt+NMoL/wPQv7U/CGBCi3viNDVKwc36I+uZaLRyPZZfzQN9K0HfZOMldCk4sRZ4uUEUwwJQ7fYJGHvUdulKGOau3HkN1pBDBOT90bb58X3zorcagE4E7P34L0PVSXgmnNhoqPC/lAtc1qaY4K93JyuWApWbylomxisaDCLRv4XcPwPk1VqUl2cYPms0Lgzr8/FGTQ4qetJtwGCcIjB498DZPHSTfcWdg4IvD6vZXC5YBr24cH10Ldv93PkPqNDKpwEOJyPr+IGhJFtO0l2I2UVYK1eaSqup3fSB4ir+gMiaXoCaDHl2qfQAOgE0MMJv4WLAyWNtKj4+qeCKABne32pxJUnO61eU/A6v0PWePOHsbPjNatjOqmxSOywrDMZF9zDcckE3Qxl2+YjBHNs66XniOtX16OZ9t/JsmDuKYMXhVlZLAVlyG0n58g3buH4MGwsV8SBlDmvtnFDm6eF2nGWSGVYrmthbSCWDsfQcL1jBL4hOxfwWrzKDmksGMlI0Ul/xTxEKpyBzoqrAK563DGSsqtG0N5FJ6T6OtgujCs9iiJI+Rh/GVu3PQlwXxCbAzYQalGd2AOjQeDNug4wD4m/Z2Edv9//H3JMsnQQ4kObK3VZx6gpNJM3Ol/lky1jatNTBHZ0r3ol9uO0E6ZidLmcsRMXe6b1XobRpoH8akB1PPWHvqoW4ZHb9A/roY5TpjErpvigreYO31IRz36YCFY6dTLSoWRHIivQg4L+jdYsOuvVwe/K7uMCCkyHzkjsUrytAonW8WZUCA8LFvjt5FlsNVhcLhJgEKtJB1V6HACiarI4BZNwTCwDwD5jPEJHYmAWgQ7bxEm/UFe1Q9/CZ5+0pvXV3k7bTaSYqLzcy4hjf81swnjBlX64Mf10ZxYRybXCITW/wv/MYNjbtgb/YDi5hrJWOpGxo5OSOIaDxJ+7bAPFQdPdRl2h8Qqx1FI5j8a1a5OZvPZXcamm31vDxmEj9uxxOwEkoa8fKtTv8BOhw1bmPK4xOAui1LyH9S+h5RUMnxZ7XaDrJ0WXQwzpGSD3jyytRQzuK9dHuk84YtkIYFzt7Ftb8cO+ofgQOIft/ipn7r0ARmsmLrwhDU+p4C/F/aH5LUtGYGM/jz4z4Nd/ZAakn6JMvrGvQL550053k5/KbexUjYmnqeDN8eXvHOvI5zlcMJYY3B/ohwzZePuZLrvP/nHnRrCjQ0GEV3JmE0fF+E6duPun9wne14quTs5Df6JGhtfYSAm0WpwLjna0YGXtYZ4lv5g3lTKk6pzsP6txLz74CovO+Qc9rhoVNFijp3cFJpMt7vUs8em4+uBpSb3lM2ENZ+pt8mBv3V4Z55BYlCc9gtHz/EBChoo5KbR8yL511D4HI5rRk06gNkLOJlgs9pq8R3IUhfMkaboaso7KobPma9gXZuJm2pwr+Rg4Em/W5ZGJvecZdF+bVxJNzcjPo9dVxvWQGbcB9tp+zzl2W4xiIDgBtTZNlW1drwCVmvl/d6dYKhqNFYcDko2AYszL2DpikqsiMNrHH+tr6vE5FNirXl9uiRkDRq+kq74mdTbWHTaViBYLoJRD1w0LMXzI6dMf4oaQjrUDIzrKXcybsm0f/Toqu1K86Pq3AaTuZQMx5aCymubvV0Hp+4WQeays2qqn/KHroc6jG0b3ZLFbeoojs3rbcEvCWGEha0O9d/SWtKeZPz17UT9z+SmoMaPmJz+HstVWXrSTM0GIhiCTzPZqczqW5qk2eYhrYWgvbc4IoDUbYrbVGQvYWLjxV/2cWE0iG7zP6xE7T/ossct5Sasj2X65MokdLFGowRis1eaU9E+Nopf2y2a+GnIhbsScjWDz5t2m1/4urD2IeW9unoTw0UyO8caw1aYHKrIRrdOIu9qD2XYaghPGdIRTBKHD2hA3kmaPTuzxz/m7xsSR3hRIAFNfVAYlXqV+fKEetBYf7Ezwz71KV4v6bn3RHc9LFOvS7BDooxaC1kSukZHcwt77NjL2VQmvTasibJ1PO7akzpCxJNBMA2tbVZhp8zyb1kR4F+txsXQsVjH0kaCH+7ZhByLeEUouK0FlLW6G/Rhf9L3kxXYu1bKQgSnHbFLTNtr8rezwafKvVG5FSmMuYkpw+z1EV1dpxGVaQ2UhmpkVLlsAvi5hfs/pjXvJ3aqomW1p3p2rXpjtOD12et6sVpdnED0LicoLVjOZRMMbkGC3SGgcEhsFqnC56pYLYSys0F2/G05Sw2NVVTiSVw5VyuOuSReb8HyxW+e8ZBTcpQf+6IL3Udn7EQprW7Qrm2RU6VKirGkYsBjk2Lo+XRSzdYWdIL0UmvcrgxOQij4Flf0fxzdyIvDuEM578vQt4dqIMW1k9xPFDhOeYGlv+/ahcIi19KGJzxQb5dp/geegQJ8KoKt5QGWaDhqWJ7fWA30E2nUeumQDGHqPllvj2T18pVUOBsO1NPUtvw3MGeiGzWaxN6dVD25Ajs4ZRMN728I5AIs2ggsAVofY17VNqtqQb44wumhq22fvEf0iYhyGIwGR5a1gn4ZoRVl37sq/l0/LceTBzsL/2T6zHOTaGl9oMyipHs8Hpck6IIJJE8rQC7wkFilvhOQplQVjdrfIa5Oy771eWU6Ds/rdvpX2zJ983W5wl/s64SjEaMsaMBRG6ymjnbkG0wFrxY6a/yQnRNJSGaC9guiOpLVqhsmy9xKUTQB1nGVvS42n+fJfkEeL0RJazyJ2kxl5g/KeYsZ82KyfLo6OrVrEJy+GuuASKfZ7fh+ZMEe9CR/7cfj/ZLKIHjcD4Uvis4JnSmhU/Yz2e22jCM5mldKeqZR6yW3hYZBhAHspnI4mFmK1q75+n6V3WXlnKzG+QGwhzJ8wMi36hNVVAADC79PfWiJXj9XNYQrzfDsPBWVkIs0Adqpp5anzdXg/HAVX5tU9dkWLus68xuXBUKeUWZuGDHMFJFCb9GBcta2WFQiBSKGnFnc+UF8B+vo2fyhWy7+TMnH0QWsLkVIGz2Gz3uIZuJDv36efoqhm3FOdkVZomCcczCWXVsKdOpWWfnpwDpHHd50IgUSmfqMiUE+gQL/LysbSRavXPn1Oq79RGipDS2nk34NCZJ/r1hfya+VwHnjLd0dOSXL4EppumJ0/tsjPYvwBqPoy4uZnaMHt0IgYBbBEqQlf/s9lBR2eBMvSTSCDUs/XTHT/K5FL7+HmTxjuvRKaTnlg0SPtGdm9gLFxmEq8dt4CLFacDhbW0GSY0TJ9T3aTUniwL4Ee3ekqQxa77V/jh2GpVxrGjHNf3MkdvIYaDVfpKj+YA6NdMTcPgnouSOeJyFFlmZJcE9u+pk0SN2hK0aVaOIri95PdtNdVs/F0T2y8P7dsTwkYbsyZR65Q/nK+bEE2vJBP/hywytr1dg7nab15TRw82pL2S0YTd2ciffg9tob/nSJ8BvbiAQrBTZ0tD4cyHlsyytUmfgQXFkAsnM0RLTMB95SyTpnGkHe1bR/6e3Rg2KKgy5kvHLR6xO9CeIhareHGgS6voht4ugEPD5/EGaMJQSFQgQQT2RiD8Q3NF7+dL36Sos3a52DCkuAULLeA8wdmm4NO+W5e7RTB/LWxL2mltbhEvFJVkO6HtOBFj9LTEN19p6D8Vn3WM/nXoy5s963Ptvsm9fEbgcEkdXLRpX7enId6R87KdHwM+xy2YXaTf3R13aBcnSh+xkRlxUzRU8pVmvDqxxh5yUynhyeuRgQPydZ3egdLYyNR8YFXaYRAcVGtjHrCGrgv/oEr6V6reu2s7Dbd5hB2XS0Yg5l432Uv6vtlDGhAohyKPbSXqgCZsm2NGgdj6anBnZie2LRMNPvPZOpKWpBEWZ4g2z94HSDkeY6glmZpD3jiDAPSthY4bd876VrNOfivKgmNQyj/yc1Qm12FZDtfd4ut6iy/165/LUglb5xC4BbZ3kdtVMV+N8azSQwvkSYM4imbLOW7i/FIDUaeOko5A3gxgmiUn/bQvGs3o0/FQvIKT3UmD/fl+k2he3QXTMi2Tenj71/dbV+k7DsHRC/q5emE6M3zEwecncFmGCQGSWiVUGHQwZJzoIY5gwYaq8bTz+6WpKdwUb8k1H208FYnkguVIjICIKx5e3v4K44gwe+Q8ROBJnSt5ZcWZkBLS6mj0pGcBJ8b7y3zbQQnog2veKvp3QuapkSehKoHTiSpXvSIK78sO0uhgjVkhRjLfCFOLA2ALxSs/TeURfAma7DmgrtQdMx2Q6sl9mJlAeYwqQ8mGFcAdwEYKZlOv/8IOeH+WinxZaUDoimo8qrxPUyCvINnmyELCndcktxIuhKbAEORLXFnL38nP9BJ7oumof1XgAGjURSCMCLXUMvY7LfpmgpTm42VvKow1Jj2g1r27GJsNcAwTq7jDXrpIfEpuqGZ9HnlIHZ3WiKGu5nnoWbu+0RG4OypSHrKgYs5B+tCTizlBoZ5UCArqZtyY9wxUF2eFuVuQSNLxMOJtPJzj9dhkjBoeXGyVPFcsQEzxcB03jNuN8/r2OlSNAsSstsyAGDeEEaX+5egt2XlIm2OqQzF4nRTFPfSGb7ZrOIOFwB2/sW9LW5xLjMqdaQK/vEfJE2TJ2VTcleqX1sPgqFqognqoHY1e94NxwK4fliLD5Hmz7lXJGsqMF/QEG/qF6Kb/E1ElqQKxzs/UI7aDPCmkzh+5zVmxyc75AjV+WKZx6mLENhJFFL0LqYMvPERnF76W5Jhygt+W8Jbj4lmGymzmf/EApzmAZbwtAag1rVyxNVO7vHi3/wSdKpzznY6VEnClKn8E+diqniRIPD/PDMgMoUMRhrz939PMKj/QyPw8NngT/UIu15yztrh8bftvzRGJoiutyt0PiLlGi/crR49A+oqzEnfKyrpyUY5IgY7nR1cKeMTrtJUSF+w/FJeQJOBnHwrHg6TFNNkwVcE+mczlLD0I+aBTFJ5DVK5inIcuvXI8L4hGDNgQpxz55KCVs+C81zkE+IHrBAjvibZC1Bpd/IviwrWitmM2DYi3G8wMQe/iS3wrcS6G5CutyOpggWdwbOu6exCVKG1agy8JTI9vT2jkkgjS46DRQhUBpv5Rrw1UAIBHb+w1obvv+mvDRBs7KPdXql1O+q+kDKFpt1IiGo67C1gtIRsPBGY7/vWC9UuN3Z6zB7OlHCPuORibVRx0Z4hdJK6aKKLgeZ+swwFVGGNcOPdOFpH2nJz0UlcRM6vNoc6vO6wVZiM6NG4rw87lY0zB2yo6TLywZyID0j4KiR6/ta2a7A/Dl2Ist2gxyOFaoD20/I76v6l/0h9OVxwp0XSLsYI/g55nBuaY4cdTkC3ov6h9RaFoLlVFAPS9uUiByYB4qKngRcrY/KbJB6vqZAc7eFPMc+puzXFsJlK+MngjTgqfzUJ5EwjtuYdrlkIKaHmgwYUdgyzsigcqJKhmvk+CSEW46HbjnnierwQv2tm5GCkuR41NiPsnA2HdtIaxtU2sjOKvntQuczSKIymg05mTk1gaaPWmW4buWldLiYglZ+/26wJlN19kee88BfXJuvxu5zE2Xda6RUFXfdqOmcBgc7vtPHjnzjdcOdaIkjXBBDYddTPyU5xo9DZPBogkujZKX4EkDlpypLKfJkK6wqdfOBBGX5dVx+1lTk09sgHHhmTNxzw3h+WR+YnlVazT2e5PIVXHpcvyBG/O8wnj7aefd3Z4jaW9P1vGPDGqCV11Bk2KvE7qZ6YjDkRsrdUYMm43zOqFIKGsXuVepAWlDmoh2OGeauoQnLN5HsT63m0D9b+Go5PNysUi3NT3pwQVubpTG5Kz/516XxYvd02XBTe30V6bqb/gECE7z7/iPkxd/Y9JIrykcRgm0b/xBszrgL0hhSpROXo1dhsWbLfidDqMoKw3Za9Nzgiix3kUC7Ml9vv8/TOcc43ZdSc/sxYLMGHE3Pwnpn4uNvgNtc6mkQ45XwQxoofXsTy3PEnR7szOKnj0wrn49PfrVczWxTIrOevWEtP3xLfegHvLonoWVWdgiC5ffSy+0C5GfqENy3vORd6hms4l3j9+depUA4QBrGzd+CqeBDKUu2y8nwYPJxTheK/oplSPdc/zmX56bECDtg1Wb1O5fayDRaDe8v39jtbj/i6NhpZdN1MUreHG+iImCD7NrtNA/NoU7eOrvyBkRDBFwIPnGd7/OVaCAi0Oi1DoK+fvnAPwu+dejKhgBf2k975qijvWyY2I10czBvfR8AAlSGeS4jom0g+cNM/j9H0k9PG5LohwxcvY4c8mY4xwRqeBIzvUYRh5xz7zrW7KptWtkyncTLiyTTg4W4Os/dhXliSG2llBzJCa7GkgO8u6wM5v0vZbVorWVAZZE90dCVeYw6qikZdRbg/37BNLEfU6CXG2e+x8hSltKeJspvXgU/cOCw5XVII1QJIEVOyLYFs+Nn6b/B6cp7LOE5zQQVv/BK9+8nepnOgUIQDyKGLNeCkhjnrf4Jjzg90yqWuDuNUL17yV5B2tqmS/KGcXFATOFygOXWguHu/A5MDlp4px+6yLmGlaQlCxOWisSfBpnqyEc31V/Pr4poGpYcfC8L1T1pSaWpORwvtTXnEZval1HdMr7wQRbI6IUhTjAMCG/cWtI2/bVC0v5JjH8UtLAsxAvdj6UHOhWOBborxRVEB0h2+iDN0gTuStpA6kT29iTeoF5XH1/UYId7D9YRflPQGz0C0zNO0gPtgZwjvvSb1eAgxF8yCzTuoS2wp/Y8d381cSmH4pgY+Z85iPY4pe0IltIKbR3GFHvxi7S71hlNTbIzf7S8ap8GBsO3EvnxDFXTkE+TDogw8jD2vtql89zakXKg4uHzc53Di4OLtkv8/MPkHjUtRnDaXBABFbN3mGMcVvWqm+kiUttQSG3/kC6chNyqtaM1ffZrkntc/KPMds44gBv2TU5iM6Ni+GQ4LbLHyLFDkD/jgFbNeRoUzSbrENti2xAjmhcla8MO26K+rnsucPx2kwKvvUVwxCJreq+xp+pQyZ74mPL0XqDM1t9DdkrL8EYVPLerRqfw/Bm4qQFbb4/2QIBgxWtFb1hVW0nfcikdyjEt3KE0XXDWcAt1o7XhGiHY4OjRZu48deZ8YQ/3K9o2AKzNWY3O0vwW4yk6CfENQ/6522eZYQ3UIIBAQFoRg6AiW5zbp85gju/tmtLz1ax5nNiC3fnFlI3TN69+a1VTakWZV7EnPtBb8o6218eX1d3meFbSRdgz97Yfz8S/Q6y3Bur1sa77+aOOwGyDdSgeLBcEIEwpmjp6zr7V3nXl8OQKI5V5J2zauBvcnmlFRh17Ecfnij5wGiO+rXYEizpXiWqc5kS/cRB/1dToqTylHFWInZsfxRAjKkAgP4oqrbv8Qc5e0FEpt57l5vkn6vJrP/WDUFuxLFimAwETOeUCKvYzGPvL1HATfgxTRu9ilZAIXcqfG9CgSxDUV1Sw4RBKdKChiahpaYUe4+kihXHJBZrb6jEYQ5vedxVAQSiWi4nEz+5gRpa9YDlkXpX/qonXhHCcz5LCH2yUWNXF4QxeLkNQjADWHHmDkugqr4YiCAlYNAEVBqFvX7P9J0ZYEuRxd0QyJCAoqXUfM3n4v+uiBbIOIV6ZSdKfjeBL46eFXoIVrrYgpLC9tgComgSDSkULqKFLEYEl2IFr7bVNfiJZ1DO+9HYZVes94OClSRjioR+B0vy4c5XGVLkAoJPLOiMPAKSpxGfZrPO5QGJUGh9FSjnVy3IALoHCjt/bWB7wvhLA8p84kBIlcdFwignN77SFEWxauFtMGH+eH+JuF73RxCqnhSgVq5SiEBpM5uWAR6nfHeU2+NKK/ZAz1rUU18zHjIUVc4tGKxc5SeaO1LgXrGC/Y5X3rMgq+v+ieFyINkyfabl8Hr/X2OxUNLpd8jQnjWr16K/dtfxaekDkC8Hxa7X0CqRjgLjxVJII2L35GIDF+IolJgQi21RXSWlyN3oNQ2UmzrODNgxYocwaCxeVRwLBOdAPYm7d43aKK+xWHbFFiWdNNUalNLwWVnQMyvDNU5f5XscXsXvK9s9vQ5miYlcPZcU/3P3x4io50RrdsKk1vDTjrFhys9q+9IgRRSnH1PEHQOHu828TSbRAEkLwXov8UEDtZA=" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['MasterPageForm']; if (!theForm) { theForm = document.MasterPageForm; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/WebForms.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ window.WebForm_PostBackOptions||document.write('<script type="text/javascript" src="/WebResource.axd?d=pynGkmcFUV13He1Qd6_TZDy7_GOIpjJ0Ev_gCdQYqqHk_ZWFLV5XISDcYendLTMgPoYek08VT5y3fOFST6xT6Q2&t=638628063619783110"><\/script>');//]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/MicrosoftAjax.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys._Application && Sys.Observer)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=uHIkleVeDJf4xS50Krz-yKqyI6ItVec4s3idbjHVhZG9J4GiEigPlJ1Pr7dbHMCyIOf7kxfX3Nb7yVtUXhwQ7AOu-iPRjdC_l5vxB_gc6Z3Dxd5tRPLJv-GNFNwaN0H-W3X3hfs6Qrai_oPPvnAUre8zbJUdf1a1YJ0rNRsMv-o1&t=2a9d95e3"><\/script>');//]]> </script> <script src="https://ajax.aspnetcdn.com/ajax/4.6/1/MicrosoftAjaxWebForms.js" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ (window.Sys && Sys.WebForms)||document.write('<script type="text/javascript" src="/ScriptResource.axd?d=Jw6tUGWnA15YEa3ai3FadCxOzjXo7DUqjVdZ-ppUm_hmRsjByokg8vJsbXd_vty5sSD7cLjWah6CFay_-VEpx11xzWP5I0beGdwJH7ICkEzqKBZp0aF_WH7BGPayHXieN2_FVY_LynI6wS_6mDtAk2iKQomHaPnn3KkQQDR1LTw1&t=2a9d95e3"><\/script>');function WebForm_OnSubmit() { null; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="738F2F5A" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="CfDJ8GYwqx9YzLZGmPQ2hZZF70JBGIV3uE0WPqgNJYmNRD+hQppNu7QtXnDFD3uf4kBGIbWPdYmGG9AYIs+EenF8iiph5gD2PLTUB/tz3LMa4T0kW3GpovqH7B18bGsKPpTyUhPq+jSJVOkHOCFeP9bwKCrIREyQ0+24cbVYF9jtg+k2WqyrTAPmf/XSPWvr2ef/y7L/hDBnlJzMsOfLgs/Rm+8=" /> </div> <input name="__HL-RequestVerificationToken" type="hidden" value="CfDJ8GYwqx9YzLZGmPQ2hZZF70L6tUCKVMQqCrJfbv5o42YZmePmH_dM4_5LngLqBu6uJpC-eSEykALZscgeLj9BPzFigD87TMTZu5hX8lhZplT6AME3lbkS3HPToRUhUtvVDPpkk7RfHvzY_H0iBQMKo2g1" /> <div id="GlobalMain"> <script type="text/javascript"> //<![CDATA[ Sys.WebForms.PageRequestManager._initialize('ctl00$ScriptManager1', 'MasterPageForm', [], [], [], 90, 'ctl00'); //]]> </script> </div> <div id="GlobalMessageContainer"> <div id="GlobalMessageContent" > <img ID="GlobalMsg_Img" alt="Message Image" src=""/>   <span id="GlobalMsg_Text"></span><br /><br /> </div> </div> <div id="react-setup" style="height:0"> <script> var formTokenElement = document.getElementsByName('__HL-RequestVerificationToken')[0]; var formToken = formTokenElement? formTokenElement.value : ''; window.fetchOCApi = function(url, params) { return fetch(url, { method: 'POST', body: JSON.stringify(params), headers: { RequestVerificationFormToken: formToken, 'Content-Type': 'application/json' } }).then(function(response) { return response.json(); }).then(function(body) { return body.data }); } </script> <div id="__hl-activity-trace" traceId="e686ad672b1a29100910b18e436a65d6" spanId="fc7c0bbc2fc6725c" tenantCode="SITCANCER" micrositeKey="e16ea3ed-ca86-452e-b5e9-18d717c3857f" navigationKey="5fff5c7b-097f-4e50-886e-1d4a86054dfd" navigationName="sitc24-preconference" viewedByContactKey="00000000-0000-0000-0000-000000000000" pageOrigin="http://www.sitcancer.org" pagePath="/2024/schedule/sitc24-preconference" referrerUrl="" userHostAddress="8.222.208.146 " userAgent="Mozilla/4.0 (compatible; MSIE 7.0; Windows NT 6.0; SLCC1; .NET CLR 2.0.50727; .NET CLR 3.0.04506; .NET CLR 3.5.21022; .NET CLR 1.0.3705; .NET CLR 1.1.4322)" ></div> <div id="page-react-root"></div> <script id="hlReactRootLegacyRemote" defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRootLegacy/ReactRootLegacy~hlReactRootLegacyRemote.bundle.e3e14a157800b68e8ff0.hash.js"></script> <script>window.reactroot_webpackPublicPath = 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/'</script> <script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~runtime~main.bundle.e7f477778cba7f022a3d.hash.js"></script> <script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~react-_yarn_cache_react-npm-18_2_0-1eae08fee2-b9214a9bd7_zip_node_modules_react_index_js.bundle.012593f3ef708f027ac2.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~vendor-_yarn___virtual___react-dom-virtual-05f150c4a1_0_cache_react-dom-npm-18_2_0-dd675bca1c-65c11b.bundle.8b02460446e4027ef67f.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~vendor-_yarn___virtual___react-dom-virtual-05f150c4a1_0_cache_react-dom-npm-18_2_0-dd675bca1c-17e4a5.bundle.1dbb26f4013744b692d1.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~vendor-_yarn_cache_lodash-npm-4_17_21-6382451519-c08619c038_zip_node_modules_lodash_lodash_js.bundle.8d689d0e26f432a3f17d.hash.js"></script><script defer src="https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/ReactRoot/ReactRoot~main.bundle.d9c6907ad1d4db1ca2e8.hash.js"></script> <script> window.hl_tinyMceIncludePaths = { cssIncludes: 'https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/Font-Awesome/6.4.2-pro/css/all.min.css|https://cdnjs.cloudflare.com/ajax/libs/prism/1.24.1/themes/prism.min.css|https://d2x5ku95bkycr3.cloudfront.net/HigherLogic/bootstrap/3.4.1/css/bootstrap.min.css|https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/Bundles/Desktop_bundle.min.d7804150d2a3d23b0f7bd53234959d21d94a14f1.hash.css|https://ajax.googleapis.com/ajax/libs/jqueryui/1.10.1/themes/base/jquery-ui.css|https://d132x6oi8ychic.cloudfront.net/higherlogic/microsite/generatecss/2b495af7-ef43-40d3-8f8d-d42fc2073d1a/c4603878-5e01-4a39-8159-01899f20c254/638681333986830000/34|https://cdn.jsdelivr.net/npm/instantsearch.css@8.0.0/themes/satellite-min.css|https://maxcdn.bootstrapcdn.com/font-awesome/4.5.0/css/font-awesome.min.css|https://fonts.googleapis.com/css?family=Dosis:500,700|https://fonts.googleapis.com/css?family=Open+Sans:400,700|https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick.css|https://cdn.jsdelivr.net/jquery.slick/1.6.0/slick-theme.css|https://use.typekit.net/cqp4ikw.css|https://use.typekit.net/zyl7cfs.css', tinymcejs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce.bc594acd1c86ca782a5f0446e0276d20202ffaf9.hash.js', hashmentionjs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce_hashmention.94b265db0d98038d20e17308f50c5d23682bf370.hash.js', mentionjs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce_mention.a35f893e40ce48b298979135724cd9e6ad18dde1.hash.js', hashtagjs: 'https://d3uf7shreuzboy.cloudfront.net/WebRoot/stable/Desktop/JS/Common/hl_common_ui_tinymce_hashtag.5579d26160cf6c00ace1fde0afcb2aacaf5baceb.hash.js' }; </script> <script> window.addEventListener('DOMContentLoaded', function (){ window.renderReactRoot( [], 'page-react-root', {"tenant":{"name":"Society for Immunotherapy of Cancer","logoPath":"https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates_forweb.png","contactSummary":"<address> 555 East Wells Street, Suite 1100<br />Milwaukee WI 53202-3823<br />United States<br />Phone: +1 414-271-2456<br /></address>"},"communityKey":"00000000-0000-0000-0000-000000000000","micrositeKey":"e16ea3ed-ca86-452e-b5e9-18d717c3857f","canUserEditPage":false,"isUserAuthenticated":false,"isUserSuperAdmin":false,"isUserCommunityAdmin":false,"isUserSiteAdmin":false,"isUserCommunityModerator":false,"currentUserContactKey":"00000000-0000-0000-0000-000000000000","isTopicCommunity":false,"isSelfModerationCommunity":false,"loginUrl":"https://sitc.execinc.com/HigherLogic/HLLoginRedirect.aspx?Redirect=","colorPickerDefaults":{"primaryColor":"#FF00FF","textOnPrimary":"#FFFF99","secondaryColor":"#66FFFF","textOnSecondary":null,"linkColor":null,"linkHoverColor":null,"footerBackgroundColor":null,"footerTextColor":null}} ) }); </script> <svg aria-hidden="true" style="height: 0px;"> <defs> <linearGradient id="skeleton-svg-gradient" x1="0" x2="1" y1="0" y2="1"> <stop offset="0%" stop-color="rgba(239, 239, 239, 0.25)"> <animate attributeName="stop-color" values="rgba(239, 239, 239, 0.25); rgba(68, 72, 85, 0.2); rgba(239, 239, 239, 0.25);" dur="3s" repeatCount="indefinite"></animate> </stop> <stop offset="100%" stop-color="rgba(68, 72, 85, 0.2)"> <animate attributeName="stop-color" values="rgba(68, 72, 85, 0.2); rgba(239, 239, 239, 0.25); rgba(68, 72, 85, 0.2);" dur="3s" repeatCount="indefinite"></animate> </stop> </linearGradient> </defs> </svg> </div> <div id="MPOuterHeader" class="row siteFrame"> <div class="col-md-12"> <div id="HEADER" class="row"> <div class="col-md-12"> <div class="ContentUserControl"> <script charset="utf-8" src="https://cdn.jsdelivr.net/gh/eConverse-Media/code-snippets@latest/js-for-FOUC.min.js"></script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function () { handlePageTitles(); handleSearch() handleHeadline(); handlekeynoteSpeakers(); handlePanel(); handleCTAs(); handleNavRegisterBtn(); if ($('.HLWelcome .imgButton').length) { $('body').addClass('logged-in'); } }); function handlePageTitles() { handleBgImage(".interior-page-title", "#PageTitleH1"); } function handleSearch() { $('#NAV .navbar-nav').append( '<li class="search-btn-top"><button type="button" onclick="toggleSearch();"><i class="fal fa-search"></i></button></li>' ); $('.search-bar-top').prependTo('#MPOuterHeader'); $('.search-bar-top .form-control').attr('placeholder', 'Type search terms here...'); $('#searchColumn .form-control').attr('placeholder', 'Type search terms here...'); $(document).click(function (e) { var searchBar = $('.search-bar-top'), searchButton = $('.search-btn-top'), target = e.target; if (!$(target).is(searchBar) && !$(target).is(searchButton) && !$(target).closest('.search-bar-top').html() && !$(target).closest('.search-btn-top').html() ) { closeSearch(); } }); } function toggleSearch() { if ($('.search-bar-top').hasClass('open')) { closeSearch(); } else { openSearch(); } } function closeSearch() { $('.search-bar-top').removeClass('open'); $('.search-btn-top').removeClass('open'); } function openSearch() { $('.search-bar-top').addClass('open'); $('.search-btn-top').addClass('open'); $('.search-bar-top .form-control').focus(); } function handleHeadline() { $('.headline-text').wrapAll('<div class="headlines" />'); $('.headline-text').wrapAll('<div class="headline-slider slider-for slick-dotted" />'); $(".headline-slider").slick({ dots: false, arrows: true, infinite: true, slidesToShow: 1, slidesToScroll: 1, autoplay: false, autoplaySpeed: 7000, nextArrow: '<button type="button" class="slick-arrow next-arrow"><i class="fas fa-caret-right"></i></button>', prevArrow: '<button type="button" class="slick-arrow prev-arrow"><i class="fas fa-caret-left"></i></button>', responsive: [{ breakpoint: 500, settings: { slidesToShow: 1, arrows: false, autoplay: true, } }] }); } function handlekeynoteSpeakers() { $('.keynote-speaker .HtmlContent').each(function () { $(this).wrapInner('<div class="text-container" />'); $(this).prepend('<div class="img-container" />'); handleBgImage($(this), $(this).find('.img-container')); }); } function handlePanel() { $('.resource-panel').wrapAll('<div class="resource-wrapper" />'); $('.resource-menu').prependTo('.resource-wrapper'); $('.resource-menu .HtmlContent ul li:first-of-type').addClass('active') $('.resource-panel .HtmlContent').each(function () { var klass = $(this).find('h6').text().toLowerCase(); klass = klass.replace(/\s+/g, '-'); klass = klass.replace(/,/g, ''); klass = klass.replace(/[{()}]/g, ''); klass = klass.replace(/&/g, 'and'); klass = klass.replace(/\*/g, ''); $(this).parent().addClass(klass) $(this).wrapInner('<div class="text-container" />'); $(this).prepend('<div class="img-container" />'); handleBgImage($(this), $(this).find('.img-container')); }); $('.resource-menu .HtmlContent ul li a').each(function () { $(this).contents().unwrap().wrap('<button type="button" />') }); $('.resource-menu .HtmlContent ul li button').each(function () { var klass = $(this).text().toLowerCase(); klass = klass.replace(/\s+/g, '-'); klass = klass.replace(/,/g, ''); klass = klass.replace(/[{()}]/g, ''); klass = klass.replace(/&/g, 'and'); klass = klass.replace(/\*/g, ''); $(this).attr('onClick', 'openPanel(".' + klass + '")'); $(this).addClass(klass); }); $('.resource-menu .HtmlContent ul li button').click(function () { $('.resource-menu .HtmlContent ul li ').removeClass('active'); $(this).parent().addClass('active'); }) } function openPanel(klass) { $('.resource-panel').hide(); $('.resource-panel' + klass).show(); } function handleCTAs() { $('.large-cta .HtmlContent').each(function () { $(this).wrapInner('<div class="text-container" />'); $(this).append('<div class="img-container" />'); handleBgImage($(this), $(this).find('.img-container')); }); } function handleNavRegisterBtn() { $('#NAV .navbar-nav').append($('.register-button')); $('.register-button').wrap('<li><li>') }</script> </div><div class="ContentUserControl"> <script charset="utf-8" src="https://cdn.jsdelivr.net/gh/eConverse-Media/code-snippets/background-images.js"></script> </div><div class="ContentItemHtml search-btn-top"> <div class="HtmlContent"><link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.5.0/css/font-awesome.min.css"> <i class="fa fa-search fa-lg"></i></div><div class="HtmlFooter"></div></div><div class="ContentUserControl search-bar-top"> <script type="text/javascript"> System.import('Common/SearchBox.js').then(function () { $('#AddlContentHeaderTop_ctl08_SearchButton').click(function () { $('#AddlContentHeaderTop_ctl08_hiddenSearchButton').click(); }); $('#AddlContentHeaderTop_ctl08_SearchOptions').click(function (e) { e.stopPropagation(); }); if ('False' == 'True') { $('#AddlContentHeaderTop_ctl08_SearchTerm').click(function (e) { $('#AddlContentHeaderTop_ctl08_SearchBoxToggle').addClass('open'); e.stopPropagation(); }); $('#AddlContentHeaderTop_ctl08_SearchTerm').focus(function (e) { $('#AddlContentHeaderTop_ctl08_SearchBoxToggle').addClass('open'); e.stopPropagation(); }); $('#AddlContentHeaderTop_ctl08_EndDate').hide(); $('#AddlContentHeaderTop_ctl08_StartDate').hide(); $('#AddlContentHeaderTop_ctl08_SearchTerm').focus(function () { $('#AddlContentHeaderTop_ctl08_SearchOptions').show(); }); $('#AddlContentHeaderTop_ctl08_DateRangeDDL').change(function () { if ($('#AddlContentHeaderTop_ctl08_DateRangeDDL').find(":selected").text() == 'on this day') { $('#AddlContentHeaderTop_ctl08_StartDate').show(); $('#AddlContentHeaderTop_ctl08_EndDate').hide(); $('#AddlContentHeaderTop_ctl08_EndDate').val(""); } else if ($('#AddlContentHeaderTop_ctl08_DateRangeDDL').find(":selected").text() == 'All') { $('#AddlContentHeaderTop_ctl08_EndDate').hide(); $('#AddlContentHeaderTop_ctl08_StartDate').hide(); } else { $('#AddlContentHeaderTop_ctl08_StartDate').show(); $('#AddlContentHeaderTop_ctl08_EndDate').show(); } }); } $('#AddlContentHeaderTop_ctl08_SearchInputs') .hl_ui_common_searchBox({ controlId: 'AddlContentHeaderTop_ctl08_SearchInputs', inputId: 'AddlContentHeaderTop_ctl08_SearchTerm', buttonId: 'AddlContentHeaderTop_ctl08_hiddenSearchButton' }); }); </script> <button id="SearchToggleIcon" type="button" class="btn btn-default" style="display: none;" role="button" aria-label="searchToggle"> <span class="glyphicon glyphicon-search" style="vertical-align: middle"></span> </button> <div id="AddlContentHeaderTop_ctl08_newSearchBox"> <div id="AddlContentHeaderTop_ctl08_SearchInputs" class="SearchInputs"> <div id="AddlContentHeaderTop_ctl08_WholeSearch" onkeypress="javascript:return WebForm_FireDefaultButton(event, 'AddlContentHeaderTop_ctl08_hiddenSearchButton')"> <div class="input-group" style="vertical-align: middle"> <input name="ctl00$AddlContentHeaderTop$ctl08$SearchTerm" type="text" id="AddlContentHeaderTop_ctl08_SearchTerm" class="form-control" autocomplete="off" qa-id="search-term" aria-label="search box" placeholder="search" Title="search" style="font-weight: normal;" /> <div id="AddlContentHeaderTop_ctl08_SearchBoxToggle" class="input-group-btn search-box-toggle"> <button id="AddlContentHeaderTop_ctl08_OptionsButton" type="button" style="display: none;" class="btn btn-default dropdown-toggle" data-toggle="dropdown" aria-label="search options"> <span class="caret"></span> <span class="sr-only">Search Options</span> </button> <button id="AddlContentHeaderTop_ctl08_SearchButton" type="button" class="btn btn-default " role="button" aria-label="search"> <span class="glyphicon glyphicon-search" style="vertical-align: middle"></span> </button> <ul class="dropdown-menu pull-right" role="menu"> <li> </li> </ul> </div> <input type="submit" name="ctl00$AddlContentHeaderTop$ctl08$hiddenSearchButton" value="" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$AddlContentHeaderTop$ctl08$hiddenSearchButton", "", true, "", "", false, false))" id="AddlContentHeaderTop_ctl08_hiddenSearchButton" style="display: none;" /> </div> </div> </div> </div> </div><div class="ContentUserControl"> <script charset="utf-8"></script> <script src="https://use.fortawesome.com/7f3536d6.js"></script> <script></script> </div><div class="ContentUserControl"> <script charset="utf-8">$( document ).ready(function() { $('.img-crop img').wrap('<span></span>'); $('.team.bottom').hide(); $(".team.top").each(function(index) { $(this).next(".team.bottom").andSelf().wrapAll("<div class='team-wrap' />") }); $('.team.top').on('click', function() { $parent_box = $(this).closest('.team-wrap'); $parent_box.siblings().find('.team.bottom').slideUp(); $parent_box.find('.team.bottom').slideToggle(300, 'swing'); }); });</script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function() { if (window.location.href.indexOf('#tab') > -1) { var url = window.location.href; str = url.split('#').pop(); // console.log(str[str.length - 1]); tabNum = '.tab-content.page-' + str[str.length - 1]; console.log(tabNum); $('.tab-content').hide(); $(tabNum).show(); } else { $('.tab-links li:first-child').addClass('active') $('.tab-content').hide(); $('.tab-content.page-1').show(); } $('.tab-content').wrapAll('<div class="tab-content-wrap"></div>'); $('.tab-links li').click(function() { var elem = $(this).context, link = $(elem).find('a'), elementId = link.attr('id'); $('.tab-links li').removeClass('active'); $(this).addClass('active'); showTabContent(elementId); }); $('.tab-links li:first-child').addClass('active') }); function showTabContent(tabClass) { $('.tab-content').each(function() { var self = $(this), classes = self.attr('class'); if (classes.indexOf(tabClass) >= 0 || tabClass === 'all') { self.show(); } else { self.hide(); } }); }</script> </div><div class="ContentUserControl"> <script charset="utf-8" src="https://cdnjs.cloudflare.com/ajax/libs/jspdf/2.5.1/jspdf.umd.min.js"></script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function() { $(".accordion-heading").each(function() { $(this).next(".accordion-text").andSelf().wrapAll("<div class='accordion-wrap' />"); }); $('.accordion-heading').on('click', function() { var items = []; $('.accordion-wrap').each(function (i, item) { items.push(item); }); $parent_box = $(this).closest('.accordion-wrap'); $parent_box.find('.accordion-text').slideToggle(600, 'swing'); $parent_box.toggleClass('open'); }); });</script> </div><div class="ContentUserControl"> <script charset="utf-8">function topOfPage() { $('body,html').animate({scrollTop: 0}, 500); } function scrollToLocation(val) { var headerHeight = !!($('#MPOuterHeader').hasClass('stickyNav') || $('#NAV').hasClass('stickyNav')) ? $('#MPOuterHeader').outerHeight() : 0; var location = $(val).offset().top - headerHeight; $('body,html').animate({scrollTop: location}, 500); }</script> </div><div class="ContentItemHtml"> <div class="HtmlContent"> <script> !function(e,t,n,s,u,a){e.twq||(s=e.twq=function(){s.exe?s.exe.apply(s,arguments):s.queue.push(arguments); },s.version='1.1',s.queue=[],u=t.createElement(n),u.async=!0,u.src='//static.ads-twitter.com/uwt.js', a=t.getElementsByTagName(n)[0],a.parentNode.insertBefore(u,a))}(window,document,'script'); // Insert Twitter Pixel ID and Standard Event data below twq('init','o4hgv'); twq('track','PageView'); </script> </div><div class="HtmlFooter"></div></div><div class="ContentUserControl"> <script charset="utf-8"><script type="text/javascript"> (function(c,l,a,r,i,t,y){ c[a]=c[a]||function(){(c[a].q=c[a].q||[]).push(arguments)}; t=l.createElement(r);t.async=1;t.src="https://www.clarity.ms/tag/"+i; y=l.getElementsByTagName(r)[0];y.parentNode.insertBefore(t,y); })(window, document, "clarity", "script", "g9lhesjwph");</script></script> </div><div class="ContentUserControl"> <script charset="utf-8">$(function () { $('.tab-content').show(); if (window.location.href.indexOf("#tab2") > -1 || (window.location.href.indexOf("#session-2") > -1)) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-2').parent().addClass('active') $('.tab-content:not(.page-2)').hide(); } else if (window.location.href.indexOf("#tab3") > -1 || (window.location.href.indexOf("#session-3") > -1)) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-3').parent().addClass('active') $('.tab-content:not(.page-3)').hide(); } else if (window.location.href.indexOf("sitc24-preconference#tils") > -1 || window.location.href.indexOf("sitc24-preconference#industry") > -1) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-1').parent().addClass('active'); $('.tab-content:not(.page-1)').hide(); } else if (window.location.href.indexOf("sitc24-preconference") > -1) { $('.tab-links li').removeClass('active') $('.tab-links li a#page-2').parent().addClass('active') $('.tab-content:not(.page-2)').hide(); } else { $('.tab-content:not(.page-1)').hide(); } })</script> </div><div class="ContentUserControl"> <script charset="utf-8"><script>(function(w,d,t,r,u){var f,n,i;w[u]=w[u]||[],f=function(){var o={ti:"187123435", enableAutoSpaTracking: true};o.q=w[u],w[u]=new UET(o),w[u].push("pageLoad")},n=d.createElement(t),n.src=r,n.async=1,n.onload=n.onreadystatechange=function(){var s=this.readyState;s&&s!=="loaded"&&s!=="complete"||(f(),n.onload=n.onreadystatechange=null)},i=d.getElementsByTagName(t)[0],i.parentNode.insertBefore(n,i)})(window,document,"script","//bat.bing.com/bat.js","uetq");</script></script> </div><div class="ContentItemHtml"><div class="HtmlContent"><p> <script data-cfasync="false">(function(w,i,s,e){window[w]=window[w]||function(){(window[w].q=window[w].q||[]).push(arguments)};window[w].l=Date.now();s=document.createElement('script');e=document.getElementsByTagName('script')[0];s.defer=1;s.src=i;e.parentNode.insertBefore(s, e)})('wisepops', 'https://wisepops.net/loader.js?v=3&h=P5FPJSHQxh');</script> </p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml"> <div class="HtmlContent"></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml interior-page-title hidden"> <div class="HtmlContent"><img src="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/SITC-2022/heading-background.jpeg" alt="heading-background.jpeg" caption="false" class="img-responsive" /></div><div class="HtmlFooter"></div></div> <div id="MPimage" class="MPimage"> <div id="mainskiplinkholder" class="skiplinkholder"><a id="skiplink" href="#MPContentArea">Skip to main content (Press Enter).</a></div> <div id="MPheader" class="MPheader"> <div class="row"> <div class="col-md-12"> <div class="pull-right"> <div class="inline"> <div class='HLWelcome HLWelcomeHeader'> <script type="text/javascript"> $(document).ready(function () { $('.Picture_Profile').tipTip({ delay: 200 }); }); function toggleHelp() { if ($("ul#CompleteBarHelpContainer").is(":visible")) { $("ul#CompleteBarHelpContainer").hide(); } else { $("ul#CompleteBarHelpContainer").show(); } } // Added as onClick for logoutLink on back end if opted in // On logout, removes the CREST API cookie that was added on login, whose value is a token used to authenticate to the API function removeApiToken(tenantKey, token) { hl_webapi_remove_cookie(tenantKey, token, tenantKey, "HLApiPassThrough"); window.location = ""; return false; } $(document).on('click', "span.CompleteBarClose", function (e) { e.stopPropagation(); toggleHelp(); $(".btn-group").find('button#BtnShowProfile').dropdown('toggle'); }); </script> <div class="EndDiv"> </div> <div id="Welcome_NotLoggedIn" class="Login"> <a id="Welcome_LoginLink" class="btn btn-primary" qa-id="login-link" href="https://sitc.execinc.com/HigherLogic/HLLoginRedirect.aspx?Redirect=https%3a%2f%2fwww.sitcancer.org%2f2024%2fschedule%2fsitc24-preconference">Login</a> </div> </div> </div> </div> <div class="pull-right"> <div id="auxskiplinkholder" class="skiplinkholder"> <a id="auxskiplink" href="#Logo">Skip auxiliary navigation (Press Enter).</a> </div> <div id="MPAuxNav" class="inline vertical-align-middle"> </div> </div> </div> </div> <div id="Logo" class="row" role="banner"> <div class="col-md-12"> <div id="DesktopLogoDiv" class="LogoImg inline"> <a href='https://www.sitcancer.org/2024/home' style=''> <img src='https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates_forweb.png' alt="SITC 2024 logo. This will take you to the homepage" /></a> </div> <div id="PhoneLogoDiv" class="LogoImg inline"> <a href='' style='display: none'> <img src='' alt="SITC 2024 logo. This will take you to the homepage" /></a> </div> <div id="SloganText" class="SloganText inline"></div> </div> </div> </div> </div> <div style="clear: both"></div> </div> </div> <div id="NAV" class="row traditional-nav"> <div class="col-md-12"> <div id="navskiplinkholder" class="skiplinkholder"><a id="navskiplink" href="#MPContentArea">Skip main navigation (Press Enter).</a></div> <div id="MPButtonBar"> <nav class="navbar navbar-default"> <div class="navbar-header"> <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-ex1-collapse, .icon-bar-start"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar-start"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> <span class="icon-bar"></span> </button> </div> <div class="collapse navbar-collapse navbar-ex1-collapse"> <div class="row"> <div class="col-md-12 "> <ul class="nav navbar-nav"> <li class='dropdown'><a href='/2024/attendee-resources' class='dropdown-toggle' data-toggle='dropdown'><span>Attendee Resources</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li ><a href='/2024/attendee-resources/faq' >Frequently Asked Questions</a></li><li ><a href='/2024/attendee-resources/registration' >Registration Rates</a></li><li ><a href='/2024/attendee-resources/sitc24-housing' >Housing</a></li><li ><a href='/2024/attendee-resources/visa-info' >Visa Information</a></li><li ><a href='/2024/attendee-resources/sitc24-ce' >Continuing Education</a></li><li ><a href='/2024/attendee-resources/enduring-materials' >Enduring Materials</a></li><li ><a href='/2024/attendee-resources/career-connections' >Career Connections</a></li><li ><a href='/2024/attendee-resources/membership' >Membership</a></li></ul></li><li class='dropdown'><a href='/2024/schedule' class='dropdown-toggle' data-toggle='dropdown'><span>Schedule</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li class='dropdown-submenu'><a href='/2024/schedule/sitc24-preconference' >Pre-Conference Programs - Nov. 6-7 <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/schedule/sitc24-preconference/combination-workshop' >Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches</a></li><li ><a href='/2024/schedule/sitc24-preconference/primer-2024' >Primer on Tumor Immunology and Cancer Immunotherapy™</a></li><li ><a href='/2024/schedule/sitc24-preconference/tils' >Tumor Infiltrating Lymphocytes (TIL) Symposium</a></li><li ><a href='/2024/schedule/sitc24-preconference/sitc2024-workshop' >Immune Engineering Workshop</a></li><li ><a href='/2024/schedule/sitc24-preconference/expert-lunch' >Meet-the-Expert Lunch</a></li><li ><a href='/2024/schedule/sitc24-preconference/sitc24-gww' >Grant Writing Workshop</a></li></ul></li><li class='dropdown-submenu'><a href='/2024/schedule/sitc24-annualmeeting' >Annual Meeting - Nov. 8-10 <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/schedule/sitc24-annualmeeting/sitc24-friday' >Friday, Nov. 8</a></li><li ><a href='/2024/schedule/sitc24-annualmeeting/sitc24-saturday' >Saturday, Nov. 9</a></li><li ><a href='/2024/schedule/sitc24-annualmeeting/sitc24-sunday' >Sunday, Nov. 10</a></li></ul></li><li class='dropdown-submenu'><a href='/2024/schedule/early-career' >Early Career Scientist Activities - Nov. 7 <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/schedule/early-career/speed-mentoring' >Early Career Scientist Speed Mentoring Event</a></li><li ><a href='/2024/schedule/early-career/ecs-networking' >Early Career Scientist Networking Reception</a></li></ul></li><li ><a href='/2024/schedule/sitc24-awards' >Awards</a></li><li ><a href='/2024/schedule/sponsored-symposia' >Sponsored Symposia</a></li><li ><a href='/2024/schedule/sitc24-checkpoints' >The CheckPoints Party</a></li><li ><a href='/2024/schedule/sitc24-business-meeting' >SITC Business Meeting</a></li><li ><a href='/2024/schedule/urg-stem' >URG Undergrads in STEM Program</a></li><li ><a href='/2024/schedule/fun-run' >SITC Fun Run</a></li></ul></li><li class='dropdown'><a href='/2024/abstracts' class='dropdown-toggle' data-toggle='dropdown'><span>Abstracts</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li class='dropdown-submenu'><a href='/2024/abstracts/abstract-submission' >Abstract Submission <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/abstracts/abstract-submission/abstract-dates' >Important Dates</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-guidelines' >Submission Guidelines</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-selection' >Selection Process</a></li><li ><a href='/2024/abstracts/abstract-submission/abstractpolicies' >Policies</a></li><li ><a href='/2024/abstracts/abstract-submission/abstracts-yia' >Young Investigator Award Abstracts</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-lba' >Late-Breaking Abstracts</a></li><li ><a href='/2024/abstracts/abstract-submission/abstract-categories' >Abstract Categories</a></li></ul></li><li class='dropdown-submenu'><a href='/2024/abstracts/abstract-presentation' >Presenter Information <strong class='caret'></strong></a><ul class='dropdown-submenu'><li ><a href='/2024/abstracts/abstract-presentation/sitc24-presentation-guidelines' >Oral Abstract Presentation Guidelines</a></li><li ><a href='/2024/abstracts/abstract-presentation/sitc24-presenter-guidelines' >Poster Presenter Guidelines</a></li></ul></li><li ><a href='/2024/abstracts/titles-and-publications' >Titles and Publications</a></li><li ><a href='/2024/abstracts/faq' >Frequently Asked Questions</a></li></ul></li><li class='dropdown'><a href='/2024/support' class='dropdown-toggle' data-toggle='dropdown'><span>Exhibit & Support</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li ><a href='/2024/support/sitc-2024-exhibitors' target='_blank'>SITC 2024 Exhibitors and Floor Plan</a></li><li ><a href='/2024/support/2024-supporters' >SITC 2024 Supporters</a></li><li ><a href='/2024/support/sponsorship' >General Information</a></li><li ><a href='/2024/support/exhibitor-information' >Exhibit</a></li><li ><a href='/2024/support/reserve-booth' target='_blank'>Reserve a Booth</a></li><li ><a href='/2024/support/sponsorship-advertising2024' >Sponsorship and Advertising</a></li><li ><a href='/2024/support/ancillary-policy' >Ancillary Event</a></li><li ><a href='/2024/support/sponsored-symposia' >Sponsored Symposia</a></li><li ><a href='/2024/support/sitc24-career' >Career Connections</a></li></ul></li><li class='dropdown'><a href='/2024/press' class='dropdown-toggle' data-toggle='dropdown'><span>Press</span> <strong class='caret'></strong></a><ul class='dropdown-menu'><li ><a href='/2024/press/information' >Press Information</a></li><li ><a href='/2024/press/press-registration' >Press Registration Form</a></li><li ><a href='/2024/press/media-policy' >Media Policy</a></li></ul></li> </ul> </div> </div> </div> </nav> </div> <div class="MenuBarUnderline"> </div> </div> </div> </div> </div> <div id="MPOuter" class="row siteFrame "> <div id="ContentColumn" class="col-md-12">  <div id="BreadCrumb" class="BreadCrumb"> </div> <div id="MPContentArea" class="MPContentArea" role="main"> <h1 id="PageTitleH1" qa-attribute="PageTitleH1" style="display: none;" aria-hidden="true"> Pre-Conference Programs - Nov. 6-7 </h1> <input type="hidden" name="ctl00$DefaultMasterHdnCommunityKey" id="DefaultMasterHdnCommunityKey" value="00000000-0000-0000-0000-000000000000" /> <div id="FlashMessageContainer"> </div> <div id="MainCopy_ContentWrapper" class="schedule"> <div class="row row-wide clearfix "><div class="col-md-12 section1"></div></div><div class="row row-full schedule-hero hero-text "><div class="col-md-12 section2"><div class="ContentItemHtml"> <div class="HtmlContent"><h1 style="text-align: center;"><strong>SITC 2024 Pre-Conference Programs</strong></h1> <h3><strong>Wednesday, Nov. 6–Thursday, Nov. 7</strong></h3></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-12 section3"><div class="ContentItemHtml tab-links"> <div class="HtmlContent"><ul class="tab-links"> <li><a id="page-1" href="#tab1"><strong>Pre-Conference Programs</strong>Wed., Nov. 6</a></li> <li><a id="page-2" href="#tab2"><strong>Pre-Conference Programs</strong>Thurs., Nov. 7</a></li> </ul></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml"><div class="HtmlContent"><p style="text-align: right; margin-bottom: none;"><button id="button" type="button" style="text-size: 12px;" class="button-gray">Download Schedule PDF</button></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12 section4"><div class="ContentItemHtml"> <div class="HtmlContent"><h2 style="text-align: center;"><strong>Wednesday, Nov. 6, 2024</strong></h2> <h3 style="text-align: center;">Pre-Conference Programs | George R. Brown Convention Center | 8 a.m.–6 p.m. CST</h3> <p style="text-align: center;"><em><span>Additional registration is required for Pre-Conference Programs. Times and program schedules subject to change. </span></em></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section5"></div></div><div class="row row-wide clearfix "><div class="col-md-4 section6"></div><div class="col-md-8 section7"></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section8"><div class="ContentItemHtml"><div class="HtmlContent"><h3><a id="tils"></a>Tumor Infiltrating Lymphocytes (TIL) Symposium</h3> <h4>WEDNESDAY, NOV. 6, 2024 | 8 a.m.–12:30 p.m. CST | George R. Brown Convention Center – Level 3 – Grand Ballroom B | <span style="text-decoration: underline;"><a href="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/TIL-Flyer.pdf"><span style="background-color: rgb(99, 167, 11);"><span style="background-color: rgb(255, 255, 255); color: rgb(100, 167, 11); text-decoration: underline;">Download Flyer</span></span></a></span></h4> <p>As part of the 39<sup>th</sup> Annual Meeting & Pre-Conference Programs (SITC 2024), the SITC Tumor Infiltrating Lymphocytes (TIL) Symposium pre-conference program provides an opportunity for an in-depth discussion on a specific topic in the field of IO. This program will provide an overview of the path to approval for TIL therapy, current clinical management, and the impact of recent FDA-approved therapies while exploring next generation TIL and innovative pre-clinical development. Through didactic presentations and panels to engage an interdisciplinary audience, the program aims to bring the field together to educate and promote the continued utilization and development of TIL therapies to address hurdles in cancer immunotherapy. </p> <h4>Program Organizers</h4> <div class="responsive-column-left"> <p><strong>Chantale Bernatchez, PhD <br></strong><em>CTMC</em><br><em></em></p> <p><strong>Stephanie Goff, MD, FACS </strong><br><em>National Cancer Institute</em></p> <p><strong>Shari Pilon-Thomas, PhD </strong><br><em>H. Lee Moffitt Cancer Center and Research Institute</em></p> <p><em><strong> </strong></em></p> </div> <p></p> <p></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section9"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Target Audience</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical research, as well as clinicians and those from regulatory and funding agencies.</p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Learning Objectives</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><ul> <li>Summarize current clinical management processes for TIL therapy and understand the regulatory history of current approved agents</li> <li>Characterize ongoing clinical studies of TIL therapy in new diseases and settings</li> <li>Discuss pre-clinical studies concerning development of novel TIL-focused strategies</li> </ul></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section10"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session I: The Path to TIL Approval and Current Clinical Management </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 377.953px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 73px;"> <td style="width: 15.5941%; height: 73px; vertical-align: top;"><strong>8:00 a.m.</strong></td> <td style="width: 84.4059%; height: 73px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif;">Stephanie Goff, MD, FACS – <em>National Cancer Institute</em></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">8:05 a.m. </span></strong></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">The History of TIL and the Road to Approval<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">James C. Yang, MD – <em>National Cancer Institute </em></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">8:25 a.m. </span></strong></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Melanoma and Beyond: Clinical Management of Patients Treated with TIL Therapy<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Amod Sarnaik, MD <span style="font-family: calibri, arial, helvetica, sans-serif;">– <em>H. Lee Moffitt Cancer Center and Research Institute</em></span><strong><br></strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span><span style="font-family: calibri, arial, helvetica, sans-serif;">Stephanie Goff, MD, FACS – <em>National Cancer Institute</em></span></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">8:45 a.m. </span></strong></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>The International TIL Experience – from an Academic Phase III Trial to M</strong></span><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>arketing Authorization<br></strong></span><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">Sebastian Klobuch, MD <span style="font-family: calibri, arial, helvetica, sans-serif;">– <em>Netherlands Cancer Institute</em></span></span></p> </td> </tr> <tr style="height: 44px;"> <td style="width: 15.5941%; height: 44px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">9:05 a.m. </span></strong></td> <td style="width: 84.4059%; height: 44px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><b><span>Lifileucel: F</span>irst FDA Approved TIL Therapy for a Solid Tumor Indication – Current Status and Future Advances</b><br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"> Friedrich Graf Finckenstein, MD – <em>Iovance Biotherapeutics</em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"></span></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.5941%; vertical-align: top; height: 40.4531px;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">9:25 a.m.</span></strong></td> <td style="width: 84.4059%; vertical-align: top; height: 40.4531px;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Break </span></strong></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session II: Next Generation TIL</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 397.359px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 73px;"> <td style="width: 15.5941%; height: 73px; vertical-align: top;">9:35 a.m.</td> <td style="width: 84.4059%; height: 73px; vertical-align: top;"> <p><span style="font-size: 14.6667px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction</strong><br></span><span style="font-family: calibri, arial, helvetica, sans-serif;">Chantale Bernatchez, PhD – <em>CTMC</em></span></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">9:40 a.m. </span></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-size: 14.6667px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>OBX-115: An engineered, pharmacologically regulatable membrane-bound IL15 TIL cell therapy for advanced solid tumors </strong><br></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Parameswaran Hari<span style="font-family: calibri, arial, helvetica, sans-serif;">, MD – <em>Obsidian Therapeutics</em></span></span></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">10:00 a.m. </span></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-size: 14.6667px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Exploring the use of TIL in metastatic epithelial cancers</strong><br></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Stephanie Goff, MD, FACS – <em>National Cancer Institute</em></span></span></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">10:20 a.m. </span></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-size: 14.6667px;"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>TIDAL-01: Enriching for a More Potent TIL Population with Selected TIL Therapy </strong><br><span style="font-family: calibri, arial, helvetica, sans-serif;">Barbara Sennino, PhD – </span><em>Turnstone Biologics </em></span></span></p> </td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.5941%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">10:40 a.m. </span></td> <td style="width: 84.4059%; height: 63.4062px; vertical-align: top;"><span style="font-size: 14.6667px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Open Discussion </strong><br></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">All session speakers</span></span></td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.5941%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">10:55 a.m.</span></td> <td style="width: 84.4059%; vertical-align: top; height: 40.4531px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Break </span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session III: Innovative Pre-Clinical TIL Development </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 406.8px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 73px;"> <td style="width: 15.5941%; height: 73px; vertical-align: top;"><strong>11:05 a.m.</strong></td> <td style="width: 84.4059%; height: 73px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif;">Shari Pilon-Thomas, PhD – <em>H. Lee Moffitt Cancer Center and Research Institute</em></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">11:10 a.m. </span></strong></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span>Using </span><i>Mighty</i><span>TIL to Overcome Suppressive Signals and Expand the Neoantigen-reactive Repertoire</span> <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Eduardo Davila, PhD<span style="font-family: calibri, arial, helvetica, sans-serif;"> – <em>TrAMPoline Pharma,</em> <em><span>University of Colorado Anshutz Medical Campus</span></em></span></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">11:30 a.m. </span></strong></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>CRISPR/Cas9 Engineered TIL Therapies <br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Micah Benson, PhD <span style="font-family: calibri, arial, helvetica, sans-serif;">– </span><em>KSQ Therapeutics </em><br></span></p> </td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">11:50 a.m. </span></strong></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>TIL Therapy for Pediatric Cancers and Sarcomas<br></strong></span><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">John E. Mullinax, MD, FACS <span style="font-family: calibri, arial, helvetica, sans-serif;">– <em>H. Lee Moffitt Cancer Center and Research Institute</em></span></span></p> </td> </tr> <tr style="height: 63.8px;"> <td style="width: 15.5941%; height: 63.8px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">12:10 p.m. </span></strong></td> <td style="width: 84.4059%; height: 63.8px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Open Discussion <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">All session speakers </span></td> </tr> <tr style="height: 49.5px;"> <td style="width: 15.5941%; vertical-align: top; height: 49.5px;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">12:25 p.m.</span></strong></td> <td style="width: 84.4059%; vertical-align: top; height: 49.5px;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Closing Remarks<br></span></strong></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix session-sponsor "><div class="col-md-12 section11"><div class="ContentItemHtml"><div class="HtmlContent"><h5 style="text-align: center;"><strong>SITC's Tumor Infiltrating Lymphocytes (TIL) Program is supported in part by grants from Achilles Therapeutics, CTMC+, Iovance Biotherapeutics, Obsidian Therapeutics, Inc. (Luncheon), and KSQ Therapeutics, Inc. (Luncheon). (as of October 2, 2024)</strong></h5></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-1 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section12"><div class="ContentItemHtml"> <div class="HtmlContent"><h3><span class="S1PPyQ"><a id="industry"></a>Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches <br></span></h3> <h4>Wednesday, Nov. 6, 2024 | 2–6 p.m. CST | George R. Brown Convention Center – Level 3 – Grand Ballroom C | <a href="http://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/Industry_Program_Flyer.pdf" title="SITC 2024 Industry Program Flyer" style="color: rgb(100, 167, 11);"><span style="text-decoration: underline;">Download Flyer</span></a></h4> <p>The SITC 2024 Industry Program, “Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches,” will advance the science and application of cancer immunotherapy by bringing together some of the top experts in industry and academia to provide high-level clinical and scientific perspectives surrounding new, emerging modalities of cancer immunotherapy. The program will explore promising new modalities of cancer immunotherapy, applications of these modalities in the clinical setting, and preclinical and translational studies of future applications of these modalities, including studies surrounding patient selection and indicators of response or resistance. The program will also address clinical and scientific considerations combining these modalities with other cancer therapies. Armed with a deeper understanding of the clinical and scientific information around the newest modalities of cancer immunotherapy, attendees will be better equipped to develop and utilize cancer immunotherapy-based treatment strategies that are cost-efficient, safer, and more effective for patients.</p> <p class="MsoNormal" style="margin-bottom: 0in; line-height: normal; mso-layout-grid-align: none; text-autospace: none;"><span style="mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;"></span></p> <h4>Program Organizers</h4> <div class="responsive-column-left"> <p><strong>Nicholas Botwood, MD </strong><br><em>Bristol Myers Squibb</em></p> <p><strong>Ivan Diaz-Padilla, MD, PhD <br></strong><strong></strong><em>GSK</em></p> <p><strong>Charles G. Drake, MD, PhD <br></strong><em>Johnson and Johnson Innovative Medicine</em></p> <p><strong>Jane Anne Healy, MD, PhD </strong><em><br>Merck Sharp & Dhome LLC</em></p> <p><strong>Priti Hegde, PhD <br></strong><em>Kite Pharma </em></p> <p><strong>Stephen Lim, MD <br></strong><em>Novartis </em></p> <p><strong>Giovanni Melillo, MD </strong><br><em>AstraZeneca</em></p> <p></p> </div></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section13"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Target Audience</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal" style="line-height: normal;">The target audience for this program includes researchers from academia and industry involved in basic, translational and clinical research, as well as clinicians and those from regulatory and funding agencies.<o:p></o:p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Learning Objectives</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><em>At the conclusion of this activity, participants should be able to: </em></p> <ul> <li>Summarize recent clinical development of new modalities of cancer immunotherapies, specifically immune cell engagers, adoptive cellular therapies, and antibody-drug conjugates</li> <li>Discuss ongoing preclinical and translational studies of these new modalities and their relevance to patient selection or detecting response or resistance to immunotherapy</li> <li>Address specific considerations when these new modalities are used in clinical settings as monotherapy or in combination with other cancer therapies</li> </ul></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section14"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session I: Emerging <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">–</span> What's Next <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">–</span> Promising New Modalities </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 381px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 70.6667px;"> <td style="width: 15.5941%; height: 70.6667px; vertical-align: top;"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>2 p.m.</strong></span></td> <td style="width: 84.4059%; height: 70.6667px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Charles G. Drake, MD, PhD – <em>Johnson and Johnson Innovative Medicine</em></span></p> </td> </tr> <tr style="height: 71.3333px;"> <td style="width: 15.5941%; height: 71.3333px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">2:05 p.m. </span></strong></td> <td style="width: 84.4059%; height: 71.3333px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">T cell Engagers <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Patrick Baeuerle, PhD – <em>Cullinan Therapeutics </em></span><em><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"> </span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"></span></em></p> </td> </tr> <tr style="height: 30.3333px;"> <td style="width: 15.5941%; height: 30.3333px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">2:25 p.m. </span></strong></td> <td style="width: 84.4059%; height: 30.3333px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>CAR T cells<br></strong>Marcela V. Maus, MD, PhD – <em>Massachusetts General Hospital</em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><br></span></p> </td> </tr> <tr style="height: 71.3333px;"> <td style="width: 15.5941%; height: 71.3333px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">2:45 p.m. </span></strong></td> <td style="width: 84.4059%; height: 71.3333px; vertical-align: top;"> <p><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>Replacing Chemotherapy with Antibody Drug Conjugates: The Future is Now<br></strong></span><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">Aditya Bardia, MD, MPH, FASCO – <em>University of California, Los Angeles</em></span></p> </td> </tr> <tr style="height: 137.333px;"> <td style="width: 15.5941%; height: 137.333px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">3:05 p.m. </span></strong></td> <td style="width: 84.4059%; height: 137.333px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Panel Discussion, Q & A<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Patrick Baeuerle, PhD – <em>Cullinan Therapeutics<br></em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Aditya Bardia, MD, MPH, FASCO<em> – University of California, Los Angeles<br></em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Marcela V. Maus, MD, PhD<em> – Massachusetts General Hospital<br></em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Kimberly S. Schluns, PhD – <em>Kite Pharma</em></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session II: Pre-Clinical and Translational </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 207px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">3:25 p.m. </span></strong></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction <br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Ivan Diaz-Padilla, MD, PhD – <em>GSK <br></em></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:30 p.m. </strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Pre-clinical: Next Generation of Immune Checkpoints: LAG3, TIM3, TIGIT: Biological Mechanisms<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Ana Carrizosa Anderson, PhD – <em>Harvard Medical School</em><br></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong><span style="font-size: 12pt;">3:50 p.m. </span></strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Improving Patient Selection for Successful Immunotherapy Development <br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Antoine Italiano, MD, PhD<em> – Institut Bergonié </em></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">4:10 p.m. </span></strong></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Panel Discussion, Q & A <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Ana Carrizosa Anderson, PhD – <em>Harvard Medical School<br></em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Antoine Italiano, MD, PhD <em>– Institut Bergonié </em></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>4:35 p.m. </strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-size: 12pt;"><strong style="font-family: calibri, arial, helvetica, sans-serif;">Break <br></strong></span></p> </td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session III: Putting New Modalities into Practice </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 254.539px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 72px;"> <td style="width: 15.6337%; height: 72px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">4:50 p.m. </span></strong></td> <td style="width: 84.3663%; height: 72px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction <br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Giovanni Melillo, MD – <em>AstraZeneca</em></span></p> </td> </tr> <tr style="height: 72.5px;"> <td style="width: 15.6337%; height: 72.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:55 p.m. </strong></span></td> <td style="width: 84.3663%; height: 72.5px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>The Complex History of PD-1 Combination Therapies: Independent Action versus the Cancer Immunity Cycle<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Emmett V. Schmidt, MD, PhD<em> – Merck Sharp & Dohme Corp.<br></em></span></p> </td> </tr> <tr style="height: 60.6797px;"> <td style="width: 15.6337%; height: 60.6797px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:15 p.m.</strong></span></td> <td style="width: 84.3663%; height: 60.6797px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Lessons Learned from STEAP-1 Targeted T Cell Engagers in Patients with mCRPC<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">William Kelly, DO <em>– Thomas Jefferson University</em></span></p> </td> </tr> <tr style="height: 49.3594px;"> <td style="width: 15.6337%; height: 49.3594px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong><span style="font-size: 12pt;">5:35 p.m. </span></strong></span></td> <td style="width: 84.3663%; height: 49.3594px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Panel Discussion, Q & A<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Nicholas Botwood, MD – <em>Bristol Myers Squibb</em><br>William Kelly, DO <em>– Thomas Jefferson University<br></em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Emmett V. Schmidt, MD, PhD<em> – Merck Sharp & Dohme Corp.</em></span></p> </td> </tr> <tr> <td style="width: 15.6337%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong><span style="font-size: 12pt;">5:55 p.m.<br></span></strong></span></td> <td style="width: 84.3663%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Closing Remarks<br></strong>Nicholas Botwood, MD – <em>Bristol Myers Squibb</em><strong><br></strong></span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-12 section15"><div class="ContentItemHtml session-sponsor"><div class="HtmlContent"><h5 style="text-align: center;"><strong>SITC's Industry Program, Beyond Checkpoint Inhibitors: New Immuno-oncology Modalities and Approaches, is supported in part by grants from Amgen, Bristol Myers Squibb, Greater Houston Partnership <em>(Reception)</em>, Kite Pharma, Inc., and Novartis Pharmaceuticals Corporation. (as of Oct. 29, 2024)</strong></h5></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12 section16"><div class="ContentItemHtml"> <div class="HtmlContent"><h2 style="text-align: center;"><strong>Thursday, Nov. 7, 2024</strong></h2> <h3 style="text-align: center;">Pre-Conference Programs | 8 a.m.–11 p.m. CST</h3> <p style="text-align: center;"><em><span>Additional registration is required for Pre-Conference Programs. Times and program schedules subject to change.</span></em></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section17"><div class="ContentItemHtml"> <div class="HtmlContent"><h3><span class="S1PPyQ"><a id="primer"></a>Primer on Tumor Immunology and Cancer Immunotherapy™</span></h3> <h4>Thursday, Nov. 7, 2024 | 8 a.m.–5:30 p.m. CST | George R. Brown Convention Center – Level 3 – Grand Ballroom C</h4> <p>The field of cancer immunology and immunotherapy has driven novel therapeutic options for cancer patients. However, the complexity of the field continues to grow, thus, the SITC Primer on Tumor Immunology and Cancer Immunotherapy™ is designed to provide a foundation for understanding core immunology principles as they relate to basic and clinical research in immunotherapy of cancer. The Primer on Tumor Immunology and Cancer Immunotherapy™ will also touch on emerging therapies and technologies to ensure attendees at all levels stay updated in our expanding field, while also laying a comprehensive foundational base for all SITC attendees. <span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; color: black; mso-color-alt: windowtext;"></span><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-ascii-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; color: black;"><o:p></o:p></span></p> <p></p> <h4>Program Organizers</h4> <div class="responsive-column-left"> <p><strong>Tullia C. Bruno, PhD <br></strong><em>University of Pittsburgh</em><strong></strong></p> <p><strong>Eric L. Smith, MD, PhD<br></strong><em>Dana-Farber Cancer Institute </em><strong><br></strong></p> </div></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section18"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Target Audience</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>The target audience for this annual, one-day educational program includes students, postdoctoral fellows and technicians from academia and industry, as well as physicians and scientists at more senior levels who wish to solidify their understanding of cancer immunology and immunotherapy, pharmacists and registered nurses. Patient advocates are also welcome to attend and learn basic concepts within the field.</p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Learning Objectives</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><em>At the conclusion of this activity, participants should be able to:</em></p> <ul> <li>Describe the key principles of cancer immunology and immunotherapy in the context of the cancer immunity cycle</li> <li>Review current approaches to immunotherapy including immune checkpoint blockade, vaccines, CAR-T cells, CAR-NK cells, activation of myeloid cells, modulation of tumor metabolism, T/NK cell adoptive transfer, and T cell bispecific therapies</li> <li>Outline immune monitoring techniques as well as biomarker strategies and their role in trial design and patient selection<br><span style="font-size: 12pt;"></span></li> <li>Enhance scientific exchange with colleagues and collaborators on research and application of cancer immunotherapies to improve outcomes of patients with cancer </li> </ul></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Continuing Education</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p>The Society for Immunotherapy of Cancer (SITC) is pleased to offer opportunities for physicians, nurses and pharmacists to obtain continuing education (CME, CNE, CPE) and ABIM MOC credits for their participation in the Primer on Tumor Immunology and Cancer Immunotherapy™ program.</p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section19"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session I: The Cancer Immunity Cycle</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 207px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr> <td style="width: 15.5941%; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8 a.m. <br></strong></span></td> <td style="width: 84.4059%; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Tullia C. Bruno, PhD <span style="mso-spacerun: yes;">– </span><em><span style="mso-spacerun: yes;"></span></em><em>University of Pittsburgh </em></span></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:15 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Adaptive Immune Responses to Cancer <br></strong>Ana Carrizosa Anderson, PhD <span style="mso-spacerun: yes;">–</span> <em>Harvard Medical School</em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>8:45 a.m.</strong></span></td> <td width="431" height="40" class="xl46" style="width: 84.4059%; height: 30pt;"> <p><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">T Cell Infiltration and Function in Solid Tumors<span style="mso-spacerun: yes;"> <br></span></span></strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><span style="mso-spacerun: yes;">Kristin G. Anderson, PhD – </span></span><em><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><span style="mso-spacerun: yes;">University of Virginia</span></span><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><span style="mso-spacerun: yes;"></span></span></em></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:15 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Innate Lymphocytes and Natural Killer Cells in Cancer Immunity <br></strong>Lewis L. Lanier, PhD – <em>University of California, San Francisco</em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:40 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><strong>The Role of Dendritic Cells in Cancer <br></strong>Niroshana Anandasabapathy, MD, PhD<strong> </strong>–<strong> </strong><em>Weill Cornell Medicine </em><strong><br></strong></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:05 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>The Role of B cells in the Cancer Immunity Cycle <br></strong></span><span color-m="#000000" font-m="Calibri" size-m="11pt"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Daniel Hollern, PhD – <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">The Salk Institute for Biological Studies</span></em><em></em></span></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:30 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"> <strong>Break </strong><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session II: Tumor Microenvironment</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 207px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:40 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Immunosuppressive Myeloid Cells: Unraveling Complexity to Achieve Rational Therapeutic Targeting <br></strong>Michelle M. Williams, PhD – <em>University of Pittsburgh</em> <strong></strong><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:05 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Stromal Modulation of the Immune Tumor Microenvironment </strong><br>Lan Coffman, MD, PhD – <em>University of Pittsburgh</em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:30 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Fever and Temperature in Tumors and Immunity<br></strong>Jeffrey C. Rathmell, PhD – <em>Vanderbilt University Medical Center </em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:55 a.m.</strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"> <p class="MsoNormal"><strong><span style="font-family: 'Calibri',sans-serif;">The Dynamic Role of CD4 T cell Subsets in Tumor Immunity<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span color-m="#000000" font-m="Calibri" size-m="11pt">Chrystal M. Paulos, PhD – </span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">Winship Cancer Institute at Emory University </span></em></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:20 p.m. </strong></span></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Lunch <br></span></strong></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session III: Driving T Cells to the Tumor</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 368.625px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.9062px;"> <td style="width: 15.6337%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong></strong><strong>Introduction<br></strong>Eric L. Smith, MD, PhD – <em>Dana-Farber Cancer Institute </em><em></em><br></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6337%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:50 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4062px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">CAR NK and NK Cell Engagers in Cancer<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Jeffrey S. Miller, PhD – <em>University of Minnesota</em></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6337%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:15 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Immune Checkpoint Therapy in Cancer </strong><br>Gordon J. Freeman, PhD, FAIO – <em>Dana-Farber Cancer Institute</em></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.6337%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:40 p.m.</strong></span></td> <td style="width: 84.3663%; height: 63.4062px; vertical-align: top;"> <div class="ewa-rteLine"><span color-m="#000000" font-m="Calibri" size-m="11pt" style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong>Update on CAR-T Cell Therapies </strong></span></span><em><span style="font-size: 12pt;"><br></span></em><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;">Eric L. Smith, MD, PhD</span></span><em><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;"> –</span> <span style="font-family: calibri, arial, helvetica, sans-serif;">Dana-Farber Cancer Institute</span></span> </em></span></div> <span style="font-size: 12pt;"></span></td> </tr> <tr style="height: 69.5px;"> <td style="width: 15.6337%; height: 69.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:05 p.m.</strong></span></td> <td style="width: 84.3663%; height: 69.5px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong style="font-family: calibri, arial, helvetica, sans-serif;">Immune Checkpoint Therapy: Identifying Mechanisms of Response and Resistance</strong><em><strong style="font-family: calibri, arial, helvetica, sans-serif;"><br></strong></em>Padmanee Sharma, MD, PhD<em> – The University of Texas MD Anderson Cancer Center </em></span><strong style="font-family: calibri, arial, helvetica, sans-serif;"><br></strong></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:30 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span color-m="#000000" font-m="Calibri" size-m="11pt" style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong>Break</strong></span></span></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table> <p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session IV: Influencers of the Response to Immunotherapies</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 207px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Modulating the Tumor Microenvironment with T cell Bispecifics <br></strong>Sumit K. Subudhi, MD, PhD – <em>The University of Texas MD Anderson Cancer Center </em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:10 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Developing Personalized Cancer Vaccines <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Stephen P. Schoenberger, PhD – <em>La Jolla Institute for Immunology </em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><br></span></strong></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>4:35 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Modifiable Extrinsic Factors Affecting Anti-cancer Immunity</strong><br>Urvi A. Shah, MD – <em>Memorial Sloan Kettering Cancer Center </em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-size: 12pt;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong>Intrinsic and Extrinsic T Cell Factors Governing Tumor Response to CAR T Cell Therapy</strong></span><br><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></span> <div class="ewa-rteLine"><span color-m="#000000" font-m="Calibri" size-m="11pt" style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">J. Joseph Melenhorst, PhD – <em>Cleveland Clinic </em></span></div> <span style="font-size: 12pt;"></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>5:25 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><span style="font-size: 12pt;"><strong style="font-family: calibri, arial, helvetica, sans-serif;">Closing Remarks <br></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Eric L. Smith, MD, PhD – <em>Dana Farber Cancer Institute </em></span><strong style="font-family: calibri, arial, helvetica, sans-serif;"><br></strong></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table> <p></p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix session-sponsor "><div class="col-md-12 section20"><div class="ContentItemHtml"><div class="HtmlContent"><h5 style="text-align: center;"><strong>SITC's Primer on Tumor Immunology and Cancer Immunotherapy is supported in part by grants from Genmab US Inc., Merck Sharpe & Dohme, Corp., a subsidiary of Merck & Co., Inc., Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals Inc. (as of Sept. 19, 2024).</strong></h5></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section21"><div class="ContentItemHtml session-0-workshop"> <div class="HtmlContent"><h3><span class="S1PPyQ"><a id="workshop"></a>Immune Engineering Workshop: Building Bridges Between All Aspects of Engineering and Immuno-oncology</span></h3> <h4>Thursday, Nov. 7, 2024 | 9 a.m.–5 p.m. CST | George R. Brown Convention Center – Level 3 – Grand Ballroom AB | <a href="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/2024_Workshop_Flyer.pdf" title="SITC 2024 Immune Engineering Workshop" style="font-family: inherit; background-color: rgb(255, 255, 255);"><span style="color: rgb(100, 167, 11);"><span style="text-decoration: underline;">Download Flyer</span></span></a></h4> <p class="paragraph" style="margin: 0in; vertical-align: baseline;"><span style="font-family: helvetica; font-size: 12pt;"><span class="normaltextrun">The SITC Immune Engineering Workshop helps SITC advance the science and application of engineering and cancer immunotherapy by providing relevant and engaging content to basic, translational, and clinical researchers. This Workshop will explore the recent advances in engineering, artificial intelligence, and cancer immunology and how these fields can converge to effectively address current hurdles in immuno-oncology. The Workshop will explore practical solutions to clinical problems via interdisciplinary collaboration between engineers, clinicians, and scientists. Armed with a deeper understanding of engineering and artificial intelligence in the context of immuno-oncology, attendees will be equipped to effectively collaborate and develop more effective tools and treatments in immuno-oncology, potentially impacting clinical care and leading to better patient outcomes.</span><span data-ccp-props="{"201341983":0,"335559739":0,"335559740":360}"><span class="eop"> </span></span></span><o:p></o:p></p> <p class="MsoNormal"><o:p> </o:p></p> <p></p> <p></p> <h4>Program Organizers</h4> <div class="responsive-column-left"> <p><strong>Daniel S. Chen, MD, PhD <br></strong><em>Synthetic Design Lab, Inc.</em></p> <p><strong>Elana J. Fertig, PhD, FAIMBE<br></strong><em>Johns Hopkins University </em></p> <p><strong>Kole T. Roybal, PhD <br></strong><em>University of California, San Francisco</em></p> <p><strong>Stefani Spranger, PhD <br></strong><em>Koch Institute for Integrative Cancer Research at MIT</em><em><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-ligatures: standardcontextual; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></span></em></p> </div></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section22"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Target Audience</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="paragraph" style="vertical-align: baseline; margin: 0in 0in 8.0pt 0in;"><span class="normaltextrun"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;">The target audience for this workshop includes engineers, chemists, material scientists, and AI computer scientists as well as basic, translational, and clinical researchers from all work settings with an interest in advances in engineering and immuno-oncology. </span></span><span data-ccp-props="{"201341983":0,"335559739":160,"335559740":360}"><span class="eop"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif;"> </span></span></span><o:p></o:p></p> <p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Learning Objectives</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><em>At the conclusion of this activity, participants should be able to:</em></p> <ul> <li>Describe key or critical issues in engineering that can be addressed by collaborative approaches between engineers and immuno-oncologists </li> <li>Detail engineering-based approaches to modulate the immune response and promote anti-cancer immunity </li> <li>Analyze cutting-edge basic, translational, and clinical studies of engineering to incorporate new research and techniques into clinical applications for cancer immunotherapy</li> </ul> <p class="paragraph" style="margin: 0in; vertical-align: baseline;" paraid="242423108" paraeid="{8f7afce1-c34b-47b3-b433-87c8c88cd9b9}{82}"></p> <p class="MsoNormal"><o:p> </o:p></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section23"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session I: The Future of Immune Engineering </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 373.219px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.5625px;"> <td style="width: 15.6337%; height: 62.5625px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9 a.m.</strong></span></td> <td style="width: 84.3663%; height: 62.5625px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Introduction<br></strong>Stefani Spranger, PhD – <em>Koch Institute for Integrative Cancer Research at MIT</em><br></span></td> </tr> <tr style="height: 63.2292px;"> <td style="width: 15.6337%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:05 a.m.</strong></span></td> <td style="width: 84.3663%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>The Future of Immune Engineering: Directed Design and the Triple Point<br></strong>Daniel S. Chen, MD, PhD – <em>Synthetic Design Lab, Inc.</em><br></span></td> </tr> <tr style="height: 63.2292px;"> <td style="width: 15.6337%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:25 a.m.</strong></span></td> <td style="width: 84.3663%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Thermogenetic Control of CAR T cell Therapies <br></strong>Gabe Kwong, PhD – <em>Georgia Tech & Emory </em><br></span></td> </tr> <tr style="height: 63.2292px;"> <td style="width: 15.6337%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>9:45 a.m.</strong></span></td> <td style="width: 84.3663%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Towards Quantifying Tumor-immune Dynamics<br></strong>Christina Curtis, PhD, MSc – <em>Stanford University</em><br></span></td> </tr> <tr style="height: 40.3438px;"> <td style="width: 15.6337%; height: 40.3438px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:05 a.m.</strong></span></td> <td style="width: 84.3663%; height: 40.3438px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Panel Discussion</strong><br></span></td> </tr> <tr style="height: 40.3438px;"> <td style="width: 15.6337%; height: 40.3438px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>10:45 a.m.</strong></span></td> <td style="width: 84.3663%; height: 40.3438px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Break </strong><br></span></td> </tr> <tr style="height: 40.2812px;"> <td style="width: 15.6337%; height: 40.2812px; vertical-align: top;"></td> <td style="width: 84.3663%; height: 40.2812px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"> </span></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session II: Successful Interdisciplinary Collaborations</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 294.542px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 54.5104px;"> <td style="width: 15.6337%; height: 54.5104px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11 a.m.</strong></span></td> <td style="width: 84.3663%; height: 54.5104px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Single-cell and Spatial Analyses Define Regulatory T cell Populations with Opposing Roles in Colorectal Cancer Progression<br></strong>Christina Leslie, PhD – <em>Memorial Sloan Kettering Cancer Center</em></span></td> </tr> <tr style="height: 63.2292px;"> <td style="width: 15.6337%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:20 a.m.</strong></span></td> <td style="width: 84.3663%; height: 63.2292px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Orthogonal IL-2 Application to CAR T cell Therapy<br></strong>Naiyer A. Rizvi, MD – <em>Synthekine </em><br></span></td> </tr> <tr style="height: 71.3333px;"> <td style="width: 15.6337%; height: 71.3333px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>11:40 a.m.</strong></span></td> <td style="width: 84.3663%; height: 71.3333px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>From Theory to Bedside: mRNA Vaccines<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Zachary Sethna, PhD – <em>Memorial Sloan Kettering Cancer Center</em></span></p> </td> </tr> <tr style="height: 42.125px;"> <td style="width: 15.6337%; height: 42.125px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12 p.m.</strong></span></td> <td style="width: 84.3663%; height: 42.125px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Panel Discussion</strong><br></span></td> </tr> <tr style="height: 40.3438px;"> <td style="width: 15.6337%; height: 40.3438px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>12:20 p.m.</strong></span></td> <td style="width: 84.3663%; height: 40.3438px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Lunch </strong><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session III: Breaking Through Therapeutic Barriers </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 207px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>1:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(16) Engineering a chemokine/cytokine-releasing biopolymer scaffold to induce tertiary lymphoid-like structures <br></strong>Rana Falahat, PhD <span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">–</span><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> </span><em>Moffitt Cancer Center </em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:05 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(239) FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy <br></strong>Paul Beavis, PhD <span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">–</span><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> </span><em>Peter MacCallum Cancer Centre</em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:25 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>(1140) Engineered B-cells show anti-tumor activity in preclinical model of HER2+breast cancer <br></strong>Lucia Sereni, PhD <span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">–</span><span style="font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Aptos; mso-fareast-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> </span><em>Boston Children's Hospital </em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>2:45 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Identification of Public T cell Receptors for Adoptive Therapy of Pancreatic Cancer <br></strong>Elizabeth M. Jaffee, MD, FAIO – <em>Sidney Kimmel Cancer Center, Johns Hopkins University </em><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:05 p.m.</strong></span></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Closing Remarks </strong><br></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.6337%; height: 23px; vertical-align: top;"></td> <td style="width: 84.3663%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session IV: Poster Session </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 85.4844px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 46.2969px;"> <td style="width: 15.6337%; height: 46.2969px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>3:10 p.m.</strong></span></td> <td style="width: 84.3663%; height: 46.2969px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Viewing Poster Abstracts </strong><br></span></td> </tr> <tr style="height: 39.1875px;"> <td style="width: 15.6337%; height: 39.1875px; vertical-align: top;"></td> <td style="width: 84.3663%; height: 39.1875px; vertical-align: top;"></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix session-sponsor "><div class="col-md-12 section24"><div class="ContentItemHtml"><div class="HtmlContent"><h5 style="text-align: center;"><strong>SITC's Immune Engineering Workshop is supported in part by grants from Bristol Myers Squibb, Kite Pharma Inc., Merck Sharp & Dohme, Corp., a subsidiary of Merck & Co., Inc., and Pfizer, Inc. (as of October 3, 2024).</strong></h5></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section25"><div class="ContentItemHtml"> <div class="HtmlContent"><h3><a href="https://www.sitcancer.org/2024/schedule/sitc24-preconference/expert-lunch"><span class="S1PPyQ"></span></a><a id="mte"></a>Meet-the-Expert Lunch - Event is Full</h3> <h4>Thursday, Nov. 7, 2024 | 12:20–1:40 p.m. CST | George R. Brown Convention Center – Level 3 – Meeting Room 332 | <a href="https://www.sitcancer.org/2024/schedule/sitc24-preconference/expert-lunch"><span style="text-decoration: underline;"><span style="color: rgb(100, 167, 11); text-decoration: underline;">Learn more</span></span></a></h4> <p>The Meet-the-Expert Lunch will focus on unique issues related to early career scientist career development and will provide attendees the opportunity to interact with experts in key areas of immunotherapy. The Meet-the-Expert Lunch will address different relevant topics in a setting that fosters attendee/expert interactions and provides networking opportunities with leaders in the field. Experts will answer questions and lead informal dialogue to help provide guidance and career advancement advice.</p> <p>Lunch will be provided to all participants. </p> <h4>Program Organizers</h4> <div class="responsive-column-left"> <p><strong>Allison Betof Warner, MD, PhD<br></strong><em>Stanford University School of Medicine</em></p> <p><strong>Praveen K. Bommareddy, PhD<br></strong><em>Replimune Inc.</em></p> <p><strong>Youngseok Cho, PhD, PharmD<br></strong><em>University of Michigan</em></p> <p><strong>Zachary A. Cooper, PhD <br></strong><em>AstraZeneca </em></p> <p><strong>Rongze O. Lu, PhD <br></strong><em>UCSF Helen Diller Family Comprehensive Cancer Center</em></p> <p><strong>Nicole E. Scharping, PhD<br></strong><em>University of California, San Diego</em></p> </div></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section26"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Target Audience</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal">The audience for the Meet-the-Expert Lunch includes graduate, medical, and post-baccalaureate students; clinical fellows; post-doctoral fellows; tenure-track investigators, government employees, and scientists in general; and industry/pharma scientists and employees. Space for this event is limited and priority will be given to early career scientists.<o:p></o:p></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Learning Objectives</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p><em>At the conclusion of this activity, participants should be able to:</em></p> <ul> <li>Address most of their open questions and concerns on the selected topic</li> <li>Make informed decisions about their career development and research projects </li> <li>Establish connections with experts in their field of interest</li> </ul></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section27"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Table Topics</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><div class="HtmlContent"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Bioinformatics and Big Data: Career Development <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><span color-m="#000000" font-m="Calibri" size-m="11pt">Riyue Bao, PhD <span bold-m="true" color-m="#000000" font-m="Calibri" size-m="11pt">– </span></span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">UPMC Hillman Cancer Center<br></span></em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">Alexander Lazar, MD, PhD</span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true"> – The University of Texas MD Anderson Cancer Center<br></span></em></span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true"></span></em></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Bioinformatics and Big Data: Harnessing Big Data to Inform Research and Clinical Trials<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">David Liu, MD </span><span style="font-family: calibri, arial, helvetica, sans-serif;"><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– Dana-Farber Cancer Institute <br></span></em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">Benjamin G. Vincent, MD</span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true"> – University of North Carolina School of Medicine </span></em></span></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Career Paths for Physician Scientists<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Tina Cascone, MD, PhD –<em> The University of Texas MD Anderson Cancer Center<br></em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Sachia S. Powell, JD <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– Powell-Drescher Ovarian Cancer Research Foundation </span></em></span></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Careers Outside Academia and Industry – Careers in Government FDA/NIH<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span><span style="font-family: calibri, arial, helvetica, sans-serif;">Stephanie L. Goff, MD, FACS <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– National Cancer Institute <br></span></em></span><span style="font-family: calibri, arial, helvetica, sans-serif;">James L. Gulley, MD, PhD, FACP – <em>National Cancer Institute</em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><br></span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Careers Outside Academia and Industry – Careers in Policy, Advocacy and Non-Profit Organizations<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">John E. Connolly, PhD <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– Parker Institute for Cancer Immunotherapy <br></span></em></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">Joan Levy, PhD </span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– Melanoma Research Alliance </span></em></span></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Clinical Trials: Building Bridges to Bring Research from the Bench to the Bedside <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Deborah Collyar <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– </span></em></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><em>Patient Advocates in Research (PAIR) <br></em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Anusha Kalbasi, MD<em> <span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– Stanford University School of Medicine </span></em></span></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Collaborating with Industry<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Greg M. Delgoffe, PhD – <em>University of Pittsburgh</em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"> <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Ryan Sullivan, MD <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– Harvard Medical School </span></em></span></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Finding the Right Mentor, Sponsor or Advocate<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Kristin G. Anderson, PhD – <em>University of Virginia</em><br>Michael T. Lotze, MD, FACS – <em>University of Pittsburgh</em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><br></span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">How to Navigate a Clinical Trainee to a Clinical Investigator Position<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Allison Betof Warner, MD, PhD – <em>Stanford University School of Medicine<br></em>Adam Schoenfeld, MD<em> – Memorial Sloan Kettering Cancer Center</em><br></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></strong></p> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">How to Navigate the Postdoc to PI Transition (Table 1) <br></span></strong><o:p></o:p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span color-m="#000000" font-m="Calibri" size-m="11pt">Yu L. Lei, PhD, DDS </span></span>– <em><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">The University of Texas MD Anderson Cancer Center<br></span></span></em><o:p></o:p><span color-m="#000000" font-m="Calibri" italic-m="true" size-m="11pt" style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Abigail </span><span color-m="#000000" font-m="Calibri" size-m="11pt"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">E. Overacre-Delgoffe, PhD – <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true"></span>University of Pittsburgh </em></span></span></p> <div class="ewa-rteLine"> <p class="MsoNormal"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">How to Navigate the Postdoc to PI Transition (Table 2)<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span color-m="#000000" font-m="Calibri" size-m="11pt">Jennifer L. Guerriero, PhD </span>– </span><o:p></o:p><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true" style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Brigham and Women's Hospital<br></span></em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true" style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Marco Ruella, MD</span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true" style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"> – University of Pennsylvania<br></span></em></p> <p class="MsoNormal"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Industry: Building Your Career in Industry (Big Pharma) (Table 1)<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Ezo Gruyters, PhD – <em>AstraZeneca<br></em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Kristen M. Hege, MD </span></p> <p class="MsoNormal"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Industry: Building Your Career in Industry (Big Pharma) (Table 2)<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Ivan Diaz-Padilla, MD, PhD <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– GSK<br></span></em></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">Giovanni Melillo, MD</span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true"> – AstraZeneca </span></em></span></p> <p class="MsoNormal"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Industry: Building Your Career in Industry (Startup and Midsize Pharma)<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;"></span><span style="font-family: calibri, arial, helvetica, sans-serif;">Arun Balakumaran, MD, PhD <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– Replay Bio <br></span></em></span><span style="font-family: calibri, arial, helvetica, sans-serif;">Praveen K. Bommareddy, PhD – <em>Replimune Inc.</em></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><br></span></strong></p> <p class="MsoNormal"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Navigating a Career in Academia: Grants and Collaborations<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><span color-m="#000000" font-m="Calibri" size-m="11pt"></span></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><span color-m="#000000" font-m="Calibri" size-m="11pt">Rongze O. Lu, PhD <em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">– UCSF Helen Diller Family Comprehensive Cancer Center <br></span></em></span></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><span color-m="#000000" font-m="Calibri" size-m="11pt">Dario A.A. Vignali, PhD </span>– </span><o:p></o:p><span style="font-family: calibri, arial, helvetica, sans-serif;"><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">University of Pittsburgh </span></em></span></p> <p class="MsoNormal"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong>Setting Up a Successful Biotech (Midsize Pharma and Small Startups)<br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span color-m="#000000" font-m="Calibri" size-m="11pt">Rachel W. Humphrey, MD </span></span>–<o:p></o:p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><span color-m="#000000" font-m="Calibri" size-m="11pt"> </span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">Normunity, Inc.<br></span></em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">Zhen Su</span><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true">, MD, MBA –<o:p></o:p><span color-m="#000000" font-m="Calibri" size-m="11pt"> </span><em>Marengo Therapeutics </em></span><em><span color-m="#000000" font-m="Calibri" size-m="11pt" italic-m="true"><br></span></em></span></p> <p class="MsoNormal"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong>Translational Research: Human Samples to Lab and Back to the Clinic<br></strong></span><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Lorenzo Galluzzi, PhD <span style="font-family: calibri, arial, helvetica, sans-serif;">–<em> </em></span></span><em style="color: rgb(0, 0, 0); font-family: Calibri;">Weill Cornell Medicine<br></em></span><span style="font-size: 12pt;"><span style="color: rgb(0, 0, 0); font-family: Calibri;">Cara Haymaker, PhD <span style="font-family: calibri, arial, helvetica, sans-serif;">–</span> </span><em style="color: rgb(0, 0, 0); font-family: Calibri;">The University of Texas MD Anderson Cancer Center</em></span></p> <p class="MsoNormal"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong>Translational Research: Mice to Humans<br></strong>Tullia C. Bruno, PhD – <em>University of Pittsburgh</em><br>Prajwal Rajappa, MD – <em>Nationwide Children's Hospital </em></span><span style="font-family: calibri, arial, helvetica, sans-serif;"></span></p> </div> <p></p> </div></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section28"><div class="ContentItemHtml session-0-grants"> <div class="HtmlContent"><h3><span class="S1PPyQ"><a id="grants"></a>Grant Writing Workshop</span></h3> <h4>Thursday, Nov. 7, 2024 | 6–8:15 p.m. CST | Marriott Marquis – Level 2 – Houston Ballroom, Salon 2</h4> <p>This program will feature two sessions. The first session opens with a program officer's perspective from application to funding, followed by an overview of grant opportunities outside the NIH, strategies for grant writing, statistical considerations for effective grant proposal writing and it concludes with a patient advocate panel. The second session will consist of breakout question and answer sessions on various types of grants. Attendees will be able to select the table they would like to sit in on for discussion. </p> <h4>Program Organizers</h4> <div class="responsive-column-left"> <p><strong>Kristin G. Anderson, PhD <br></strong><em>University of Virginia</em></p> <p><strong>Aitziber Buque Martinez, PhD <br></strong><em>Fox Chase Cancer Center <br></em></p> <p><strong>Geoffrey J. Markowitz, PhD</strong><em><br>Weill Cornell Medicine </em></p> <p><strong></strong></p> <p><strong>Golnaz Morad, DDS, PhD <br></strong><em>The University of Texas MD Anderson Cancer Center</em></p> <p><strong>Ravi Patel, MD, PhD </strong><br><em>University of Pittsburgh</em></p> <p><strong>Aleksei Tikhonov, PhD <br></strong><em>Gustave Roussy</em></p> </div></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section29"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Target Audience</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal" style="margin-bottom: 0in; line-height: normal; mso-layout-grid-align: none; text-autospace: none;"><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: black;">The target audience for this educational program includes graduate students, postdoctoral fellows, and junior to midlevel faculty, which encompasses instructors and assistant professors who wish to solidify their understanding of grant writing.<o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom: 0in; line-height: normal; mso-layout-grid-align: none; text-autospace: none;"><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: black;"><br><o:p></o:p></span></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Learning Objectives</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><p class="MsoNormal" style="margin-bottom: 0in; line-height: normal; mso-layout-grid-align: none; text-autospace: none;"><span style="font-family: CIDFont+F2; mso-bidi-font-family: CIDFont+F2; color: #231f20;"><em>At the conclusion of this activity, participants should be able to: </em><o:p></o:p></span></p> <p class="MsoNormal" style="margin-bottom: 0in; line-height: normal; mso-layout-grid-align: none; text-autospace: none;"><span style="font-family: CIDFont+F2; mso-bidi-font-family: CIDFont+F2; color: #231f20;"></span></p> <p class="MsoNormal" style="margin-bottom: 0in; line-height: normal; mso-layout-grid-align: none; text-autospace: none;"><span style="font-family: CIDFont+F2; mso-bidi-font-family: CIDFont+F2; color: #231f20;"> </span></p> <p class="MsoNormal" style="margin-bottom: 0in; line-height: normal; mso-layout-grid-align: none; text-autospace: none;"><span style="font-family: CIDFont+F2; mso-bidi-font-family: CIDFont+F2; color: #231f20;"></span></p> <ul> <li class="MsoListParagraphCxSpFirst" style="text-indent: -0.25in; line-height: normal;"><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: #231f20;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: #231f20;">Evaluate funding opportunities<o:p></o:p></span><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: #231f20;"></span><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: #231f20;"></span></li> <li class="MsoListParagraphCxSpFirst" style="text-indent: -0.25in; line-height: normal;"><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: #231f20;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: #231f20;">Identify critical strengths and fatal flaws of a grant proposal<o:p></o:p></span></li> <li class="MsoListParagraphCxSpMiddle" style="text-indent: -0.25in; line-height: normal;"><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: black;">Optimize the process of grant re-submission</span><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3;"><o:p></o:p></span><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: black;"></span></li> <li class="MsoListParagraphCxSpMiddle" style="text-indent: -0.25in; line-height: normal;"><span style="font-family: CIDFont+F3; mso-bidi-font-family: CIDFont+F3; color: black;"> Incorporate patient advocate perspectives and recommendations in research and funding proposals </span></li> </ul></div><div class="HtmlFooter"></div></div></div><div class="col-md-8 section30"><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session I </h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 549.219px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 62.9062px;"> <td style="width: 15.5941%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>6 p.m.</strong></span></td> <td style="width: 84.4059%; height: 62.9062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Getting a Grant from the NIH<br></strong>Lillian Kuo, PhD – <em>National Cancer Institute</em><br></span></td> </tr> <tr style="height: 63.4062px;"> <td style="width: 15.5941%; height: 63.4062px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">6:15 p.m. </span></strong></td> <td style="width: 84.4059%; height: 63.4062px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Overview of Grant Opportunities Outside the NIH <br></strong>Saman Maleki, PhD – <em>Western University </em><strong><br></strong></span></td> </tr> <tr style="height: 73.5px;"> <td style="width: 15.5941%; height: 73.5px; vertical-align: top;"><span style="font-size: 12pt;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">6:30 p.m. </span></strong></span></td> <td style="width: 84.4059%; height: 73.5px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Strategies for Grant Writing <br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Niroshana Anandasabapathy, MD, PhD – <em>Weill Cornell Medicine</em><br></span></p> </td> </tr> <tr style="height: 55.5px;"> <td style="width: 15.5941%; height: 55.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif;"><strong><span style="font-size: 12pt;">6:50 p.m. </span></strong></span></td> <td style="width: 84.4059%; height: 55.5px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Statistical Considerations for Effective Grant Proposal Writing and Avoiding Common Pitfalls <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Xi Kathy Zhou, PhD, MS –<em> </em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em>Weill Cornell Medicine</em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"></span></p> </td> </tr> <tr style="height: 60.5px;"> <td style="width: 15.5941%; vertical-align: top; height: 60.5px;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>7 p.m. <br></strong></span></td> <td style="width: 84.4059%; vertical-align: top; height: 60.5px;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Question and Answer <br></span></strong></p> </td> </tr> <tr style="height: 129.5px;"> <td style="width: 15.5941%; height: 129.5px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>7:10 p.m. </strong></span></td> <td style="width: 84.4059%; height: 129.5px; vertical-align: top;"> <p style="padding-top: 5px; padding-right: 5px; padding-bottom: 5px; text-align: left;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif;">The Importance of the Patient Advocate Perspective in Research and How to Effectively Connect with Advocates<br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Kristin G. Anderson, PhD <span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">–<em> University of Virginia <br></em></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em></em></span></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Sachia S. Powell, JD <em>– Powell-Drescher Ovarian Cancer Research Foundation <br></em></span></span><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Kimberly Richardson, MA <em>– Black Cancer Collaborative </em></span></span><strong><span style="font-family: calibri, arial, helvetica, sans-serif;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><em></em></span></span></strong></p> </td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.5941%; height: 40.4531px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>7:30 p.m. </strong></span></td> <td style="width: 84.4059%; height: 40.4531px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Question and Answer </strong></span></td> </tr> <tr style="height: 40.4531px;"> <td style="width: 15.5941%; height: 40.4531px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>7:35 p.m. </strong></span></td> <td style="width: 84.4059%; height: 40.4531px; vertical-align: top;"><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Break </strong></span></td> </tr> <tr style="height: 23px;"> <td style="width: 15.5941%; height: 23px; vertical-align: top;"></td> <td style="width: 84.4059%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-heading container"> <div class="HtmlContent"><h3>Session II</h3></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml accordion-text"> <div class="HtmlContent"><table style="height: 207px; width: 100%; border-collapse: collapse; border-style: none;"> <tbody> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><strong><span style="font-size: 12pt; font-family: calibri, arial, helvetica, sans-serif;">7:40 p.m. </span></strong></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"> <p><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Question and Answer Breakout Tables (Various Types of Grants) </span><br><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Career Development Awards (K Awards, K99/R00 Grants, Late Postdocs) Breakout Table <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Ravi Patel, MD, PhD – <em>University of Pittsburgh </em></span><strong><br><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">F Grants and T Grants for Predoctoral/Medical Students and Early Postdocs Breakout Table <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Geoffrey J. Markowitz, PhD – <em>Weill Cornell Medicine </em></span><strong><br><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Foundation Grants Breakout Table </span><br></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Kristin G. Anderson, PhD – <em>University of Virginia </em></span><br><strong><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Grants for Physician Scientists Breakout Table <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Allison Betof Warner, MD, PhD – <em>Stanford University School of Medicine </em></span><strong><br><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Grant Opportunities for non-US Attendees (K99, Society Grants, European-based Opportunities) Breakout Table </span><br></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Saman Maleki, PhD – <em>Western University </em></span><strong><br><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Interfacing with Industry (Biotech Grants) Breakout Table <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif;">Zachary A. Cooper, PhD – <em>AstraZeneca </em></span><strong><br><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Low-preliminary Data Grants (DP5, R21, High Risk/High Reward Grants) Breakout Table <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Golnaz Morad, DDS, PhD – <em>The University of Texas MD Anderson Cancer Center </em></span><strong><br></strong><strong><br><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Transition from Mentored to Independent Grants (Getting Your First R01) Breakout Table <br></span></strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Claire I. Vanpouille-Box, PhD – <em>Weill Cornell Medicine </em></span><strong><br></strong></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"><strong><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">8:10 p.m. </span></strong></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"> <p><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;"><strong>Closing Remarks <br></strong></span><span style="font-family: calibri, arial, helvetica, sans-serif; font-size: 12pt;">Aleksei Tikhonov, PhD – <em>Gustave Roussy</em></span></p> </td> </tr> <tr style="height: 23px;"> <td style="width: 15.6364%; height: 23px; vertical-align: top;"></td> <td style="width: 84.3636%; height: 23px; vertical-align: top;"></td> </tr> </tbody> </table></div><div class="HtmlFooter"></div></div></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section31"><div class="ContentItemHtml"> <div class="HtmlContent"><h3><span class="S1PPyQ"><a id="ecs-mentoring"></a>Early Career Scientist Speed Mentoring Event - Event is Full</span></h3> <h4>Thursday, Nov. 7, 2024 | 8:30–9:30 p.m. CST | Marriott Marquis Level 3</h4> <p>The ECS Speed Mentoring Event will provide early career scientists the opportunity to receive mentorship from an expert in the field of cancer immunotherapy in a one-on-one setting. Hosted by SITC's Early Career Scientist Committee, mentees will be matched with an expert mentor allowing time for a discussion with an expert mentor. Also, during this event we will provide an opportunity for networking in an adjoining area. Mentees are required to indicate interest to attend this event when registering for SITC's annual meeting. Mentees are selected on a first come first serve basis and will be contacted for participation. </p> <h4>Program Organizers</h4> <div class="responsive-column-left"> <p><strong>Ardit Feinaj, MD<br></strong><em>Johns Hopkins University</em></p> <p><strong>Robyn Gartrell, MD<br></strong><em>Johns Hopkins University</em></p> <p><strong>Sarah Gitto, PhD<br></strong><em>University of Pennsylvania</em></p> <p><strong>Tanya Keenan, MD, MPH<br></strong><em>Merck Research Laboratories</em></p> <p><strong>Ashley Koegel, MD<br></strong><em>Bristol Myers Squibb</em></p> <p><strong></strong></p> <p><strong>Daniel Michaud, PhD<br></strong><em>Brigham & Women’s Hospital</em></p> <p><strong>Abdul Rafeh Naqash, MD<br></strong><em>Stephenson Cancer Center, Oklahoma University</em></p> <p><strong>Abigail Overacre-Delgoffe, PhD<br></strong><em>University of Pittsburgh</em></p> <p><strong>Quaovi Sodji, MD, PhD<br></strong><em>University of Wisconsin-Madison</em> </p> </div></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section32"></div><div class="col-md-8 section33"></div></div></div></div><div class="row row-wide clearfix page-2 tab-content bg-white-shadow "><div class="col-md-12" ><div class="row row-wide clearfix "><div class="col-md-12 section34"><div class="ContentItemHtml"> <div class="HtmlContent"><h3><span class="S1PPyQ"><a id="networking"></a>Early Career Scientist Networking Reception & Sparkathon Alumni Reception</span></h3> <h4>Thursday, Nov. 7, 2024 | 9:30–11:00 p.m. CST | Marriott Marquis – Level 3 – Hunters Creek</h4> <p>This combined event will allow all early career scientist attendees to meet colleagues and make early connections that can be fostered throughout the rest of the conference. Come learn about the yearly activities of the Early Career Scientist Committee, and the prestigious Sparkathon program, and how you can get involved.</p></div><div class="HtmlFooter"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-4 section35"></div><div class="col-md-8 section36"></div></div></div></div><div class="row row-wide clearfix "><div class="col-md-12 section37"><div class="ContentUserControl"> <script charset="utf-8">let button = document.getElementById("button"); let makepdf = document.getElementById("MainCopy_ContentWrapper"); button.addEventListener("click", function () { let mywindow = window.open("", "PRINT", "height=400,width=600"); mywindow.document.write(MainCopy_ContentWrapper.innerHTML); mywindow.document.close(); mywindow.focus(); mywindow.print(); mywindow.close(); return true; });</script> </div></div></div> <div id="MainCopy_extraPanel"> </div> </div> </div>  </div> </div> <div id="MPOuterFooter" class="row siteFrame"> <div id="FOOTER" class="col-md-12"> <div class="row row-full footer-top "><div class="col-md-3 section1"><div class="ContentItemHtml footer-logo"> <div class="HtmlContent"><p><a href="https://www.sitcancer.org/2024/home"><img class="img-responsive" src="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/AMPCP_2024/SITC2024-logo-dates-rev_clr_300px.png" alt="footer-logo-big.png" data-mce-hlimagekey="67b5f853-bdcd-2be1-5090-160ad9540305" data-mce-hlselector="#TinyMceContent_2338b29b-686c-d08e-8f04-19a29db1b932-tinyMceHtml"></a></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-3 section2"><div class="ContentItemHtml footer-contact"> <div class="HtmlContent"><h4><span style="font-family: helvetica;">Contact Us</span></h4> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">555 East Wells Street, Suite 1100</span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Milwaukee, WI 53202-3823</span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Email: <a href="mailto:info@sitcancer.org" target="_blank" rel="noopener">info@sitcancer.org</a></span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Phone: USA Tel: +1 414 271 2456</span></p> <p><span style="font-family: calibri, arial, helvetica, sans-serif;">Fax: +1 414 276 3349</span></p> <p></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-3 section3"><div class="ContentItemHtml footer-links"> <div class="HtmlContent"><h4><span style="font-family: helvetica;">Quick Links</span></h4> <p><a href="https://www.sitcancer.org/2024/home">Home</a></p> <p><a href="https://www.sitcancer.org/2024/attendee-resources/registration">Register</a></p> <p><a href="https://www.sitcancer.org/2024/schedule/sitc24-annualmeeting">Schedule</a></p> <p><a href="https://www.sitcancer.org/2024/abstracts/abstract-submission">Abstracts</a></p></div><div class="HtmlFooter"></div></div></div><div class="col-md-3 section4"><div class="ContentItemHtml footer-social"> <div class="HtmlContent"><p><a href="https://www.sitcancer.org/home" target="_blank" rel="noopener"><img class="img-responsive" src="https://higherlogicdownload.s3.amazonaws.com/SITCANCER/e16ea3ed-ca86-452e-b5e9-18d717c3857f/UploadedImages/Logos/SITC-rev-grn.png" alt="" data-mce-hlimagekey="8680bb71-e3a3-c9e1-5055-e08862e837dc" data-mce-hlselector="#TinyMceContent_510a025b-4442-1629-33bf-9157ceb40a82-tinyMceHtml" width="718" height="308"></a></p> <ul> <li><a href="https://www.facebook.com/sitcancer" target="_blank" rel="noopener noreferrer"> <i class="fab fa-facebook"></i></a></li> <li><a href="https://twitter.com/sitcancer" target="_blank" rel="noopener noreferrer"><i class="fa-brands fa-x-twitter"></i></a></li> <li><a href="https://www.linkedin.com/company/381116" target="_blank" rel="noopener noreferrer"><i class="fab fa-linkedin-in"></i></a></li> <li><a href="http://www.youtube.com/user/SITCancer?feature=watch" target="_blank" rel="noopener noreferrer"><i class="fab fa-youtube"></i> </a></li> </ul></div><div class="HtmlFooter"></div></div></div></div> <div id="MPFooter" class="row"> <div class="Footer col-md-12"> <div id="FooterContent"> </div> <div id="MPBottomMenu" class="MPBottomMenu" align="center"> </div> </div> </div> <div class="row"> <div id="MPCopyright" class="col-md-12"> </div> </div> <div class="row row-full footer-bottom "><div class="col-md-6 section1"><div class="ContentItemHtml copyright"> <div class="HtmlContent"><p><span style="font-family: calibri, arial, helvetica, sans-serif;">© 2024 Society for Immunotherapy of Cancer (SITC). All rights reserved.</span></p></div><div class="HtmlFooter"></div></div><div class="ContentItemHtml"> <div class="HtmlContent"><p> <script type="text/javascript"> _linkedin_partner_id = "2569393"; window._linkedin_data_partner_ids = window._linkedin_data_partner_ids || []; window._linkedin_data_partner_ids.push(_linkedin_partner_id); </script> <script type="text/javascript"> (function(l) { if (!l){window.lintrk = function(a,b){window.lintrk.q.push([a,b])}; window.lintrk.q=[]} var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);})(window.lintrk); </script> </p> <noscript> <img height="1" width="1" style="display: none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2569393&fmt=gif" data-mce-src="https://px.ads.linkedin.com/collect/?pid=2569393&fmt=gif" data-mce-style="display: none;"> </noscript></div><div class="HtmlFooter"></div></div></div><div class="col-md-6 section2"><div class="ContentItemHtml attribution"> <div class="HtmlContent"></div><div class="HtmlFooter"></div></div></div></div> <div class="row"> <div class="col-md-12"></div> </div> </div> </div> <div id="MPFooterLink" class="row siteFrame"> <div class="col-md-12"> <div id="MPFooterLinkContent"> <a href="http://www.higherlogic.com" target="_blank">Powered by Higher Logic</a> </div> </div> </div> <div id="GlobalPopupContainer"> <div id="GlobalPopupContent" > <img ID="imgGlobalProcessing" alt="" src="https://d2x5ku95bkycr3.cloudfront.net/img/loading.gif" /> </div> </div> <script type="text/javascript"> //<![CDATA[ var _suppressGlobalPopupContainer = false; Sys.Application.add_load(GlobalApplicationLoadHandler); function GlobalApplicationLoadHandler(sender, args) { var prm = Sys.WebForms.PageRequestManager.getInstance(); if (!prm.get_isInAsyncPostBack()) { prm.add_initializeRequest(initRequest); prm.add_endRequest(endRequest); } } function initRequest(sender, args) { if (!_suppressGlobalPopupContainer) { hl_common_ui_blockUI(); } } function endRequest(sender, args) { hl_common_ui_unBlockUI(); }//]]> </script> </form> </div> <script> $(document).ready(function () { var path = window.location.pathname; var lastChar = path.substr(-1); // Selects the last character if (lastChar != '?' && lastChar != '/' && lastChar != ';') { // If the last character is not a slash path = path + '/'; // Append a slash to it. } $('ul.navbar-nav a').each(function () { var myHref = $(this).attr('href').split("?")[0]; var lastChar2 = myHref.substr(-1); // Selects the last character if (lastChar2 != '?' && lastChar2 != '/' && lastChar2 != ';') { // If the last character is not a slash myHref = myHref + '/'; // Append a slash to it. } if (path == myHref) { $(this).parents('li').last().addClass('active current-page'); $(this).parent('li').addClass('active current-page'); } }); $('#modalTags').on('tagAdded', function () { var oldCount = parseInt($('#litCommunityTagsCount').text()); $('#litCommunityTagsCount').text(oldCount + 1); }).on('tagRemoved', function () { var oldCount = parseInt($('#litCommunityTagsCount').text()); $('#litCommunityTagsCount').text(oldCount - 1); }); var isImpersonating = false; var padMPOuterHeader = function () { var headerHeight = $("#MPOuterHeader").height(); $("#MPOuter").css("padding-top", parseInt(headerHeight) + 5); }; $("#MPOuterHeader").addClass('stickyNav stickyNav-full'); padMPOuterHeader(); $(window).bind('resize', function () { padMPOuterHeader(); }); }); //var btn = $.fn.button.noConflict(); // reverts $.fn.button to jqueryui btn //$.fn.btn = btn; // assigns bootstrap button functionality to $.fn.btn </script> </body> </html>